Antares Pharma (ATRS) 10-K 13 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 07, 2014	Jun. 30, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'ATRS	'	'
Entity Registrant Name	'ANTARES PHARMA, INC.	'	'
Entity Central Index Key	'0001016169	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Common Stock, Shares Outstanding	'	129,928,018	'
Entity Public Float	'	'	$472,932,000

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current Assets:	'	'
Cash and cash equivalents	$39,067,236	$52,097,064
Short term investments	24,014,305	21,112,623
Accounts receivable	1,034,492	2,228,650
Inventories	6,461,051	1,002,703
Deferred costs	375,773	755,159
Prepaid expenses and other current assets	1,706,678	463,033
Total current assets	72,659,535	77,659,232
Equipment, molds, furniture and fixtures, net	6,952,251	3,583,104
Patent rights, net	1,345,177	1,123,652
Goodwill	1,095,355	1,095,355
Long term investments	6,008,169	12,015,906
Other assets	871,444	49,361
Total Assets	88,931,931	95,526,610
Current Liabilities:	'	'
Accounts payable	6,378,712	2,864,507
Accrued expenses and other liabilities	5,453,075	2,916,700
Deferred revenue	4,531,220	2,157,016
Total current liabilities	16,363,007	7,938,223
Deferred revenue - long term	1,855,196	1,037,795
Total liabilities	18,218,203	8,976,018
Stockholders' Equity:	'	'
Preferred Stock: $0.01 par; authorized 3,000,000 shares, none outstanding	'	'
Common Stock: $0.01 par; authorized 200,000,000 shares; 128,740,604 and 125,949,024 issued and outstanding at December 31, 2013 and 2012, respectively	1,287,406	1,259,490
Additional paid-in capital	243,375,465	238,745,612
Accumulated deficit	-173,295,941	-152,789,165
Accumulated other comprehensive loss	-653,202	-665,345
Total Stockholders' Equity	70,713,728	86,550,592
Total Liabilities and Stockholders' Equity	$88,931,931	$95,526,610

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Statement Of Financial Position [Abstract]	'	'
Preferred Stock, par value	$0.01	$0.01
Preferred Stock, shares authorized	3,000,000	3,000,000
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$0.01	$0.01
Common Stock, shares authorized	200,000,000	200,000,000
Common Stock, shares issued	128,740,604	125,949,024
Common Stock, shares outstanding	128,740,604	125,949,024

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenue:	'	'	'
Product sales	$10,957,932	$9,137,573	$7,630,402
Development revenue	4,139,672	7,422,412	4,462,287
Licensing revenue	849,185	2,141,309	1,220,823
Royalties	4,671,711	3,874,284	3,144,980
Total revenue	20,618,500	22,575,578	16,458,492
Cost of revenue:	'	'	'
Cost of product sales	6,990,186	6,116,726	3,623,186
Cost of development revenue	2,207,044	3,403,746	3,174,006
Total cost of revenue	9,197,230	9,520,472	6,797,192
Gross profit	11,421,270	13,055,106	9,661,300
Operating expenses:	'	'	'
Research and development	15,263,371	14,921,552	6,699,325
Sales and marketing	8,714,461	1,412,565	'
General and administrative	8,293,755	8,172,488	7,398,762
Total operating expenses	32,271,587	24,506,605	14,098,087
Operating loss	-20,850,317	-11,451,499	-4,436,787
Other income (expense):	'	'	'
Interest income	111,577	63,195	55,592
Foreign exchange gain (loss)	-8,853	14,414	-19,784
Other, net	-59,183	-53,560	13,059
Total other income (expense)	43,541	24,049	48,867
Net loss	-20,806,776	-11,427,450	-4,387,920
Income tax provision (benefit)	-300,000	'	'
Net loss	($20,506,776)	($11,427,450)	($4,387,920)
Basic and diluted net loss per common share	($0.16)	($0.10)	($0.05)
Basic and diluted weighted average common shares outstanding	126,897,247	110,185,077	96,994,779

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statement Of Income And Comprehensive Income [Abstract]	'	'	'
Net loss	($20,506,776)	($11,427,450)	($4,387,920)
Foreign currency translation adjustment	12,143	-70,020	-35,488
Comprehensive loss	($20,494,633)	($11,497,470)	($4,423,408)

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balance at Dec. 31, 2010	$6,626,618	$841,579	$143,318,671	($136,973,795)	($559,837)
Balance, shares at Dec. 31, 2010	'	84,157,865	'	'	'
Issuance of common stock	21,280,718	143,750	21,136,968	'	'
Issuance of common stock, shares	'	14,375,000	'	'	'
Exercise of warrants and options	6,020,436	44,753	5,975,683	'	'
Exercise of warrants and options, shares	'	4,475,335	'	'	'
Stock-based compensation	1,639,481	5,374	1,634,107	'	'
Stock-based compensation, shares	'	537,437	'	'	'
Net loss	-4,387,920	'	'	-4,387,920	'
Other comprehensive loss	-35,488	'	'	'	-35,488
Balance at Dec. 31, 2011	31,143,845	1,035,456	172,065,429	-141,361,715	-595,325
Balance, shares at Dec. 31, 2011	'	103,545,637	'	'	'
Issuance of common stock	53,328,188	142,599	53,185,589	'	'
Issuance of common stock, shares	'	14,259,868	'	'	'
Exercise of warrants and options	11,579,413	80,217	11,499,196	'	'
Exercise of warrants and options, shares	'	8,021,672	'	'	'
Stock-based compensation	1,996,616	1,218	1,995,398	'	'
Stock-based compensation, shares	'	121,847	'	'	'
Net loss	-11,427,450	'	'	-11,427,450	'
Other comprehensive loss	-70,020	'	'	'	-70,020
Balance at Dec. 31, 2012	86,550,592	1,259,490	238,745,612	-152,789,165	-665,345
Balance, shares at Dec. 31, 2012	'	125,949,024	'	'	'
Exercise of warrants and options	2,326,838	24,523	2,302,315	'	'
Exercise of warrants and options, shares	'	2,452,254	'	'	'
Stock-based compensation	2,330,931	3,393	2,327,538	'	'
Stock-based compensation, shares	'	339,326	'	'	'
Net loss	-20,506,776	'	'	-20,506,776	'
Other comprehensive loss	12,143	'	'	'	12,143
Balance at Dec. 31, 2013	$70,713,728	$1,287,406	$243,375,465	($173,295,941)	($653,202)
Balance, shares at Dec. 31, 2013	'	128,740,604	'	'	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:	'	'	'
Net loss	($20,506,776)	($11,427,450)	($4,387,920)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation and amortization	558,280	231,028	168,173
Loss (gain) on disposal of equipment, molds, furniture and fixtures	0	119,429	-30,000
Stock-based compensation expense	2,435,260	2,025,532	1,872,772
Amortization of premiums and discounts	210,057	66,324	9,761
Changes in operating assets and liabilities:	'	'	'
Accounts receivable	1,198,643	310,813	-1,300,995
Inventories	-5,460,365	-118,365	-629,510
Prepaid expenses and other current assets	-1,222,962	-177,714	-156,571
Deferred costs	381,792	444,279	212,097
Other assets	-821,975	-18,012	0
Accounts payable	2,528,740	724,802	365,522
Accrued expenses and other current liabilities	2,534,293	687,297	406,824
Deferred revenue	3,196,862	-3,340,951	1,543,840
Net cash used in operating activities	-14,968,151	-10,472,988	-1,926,007
Cash flows from investing activities:	'	'	'
Purchase of investments	-21,129,535	-30,166,239	-15,053,981
Proceeds from maturities of investments	24,000,000	12,000,000	0
Proceeds from sales of equipment, molds, furniture and fixtures	0	0	30,000
Purchases of equipment, molds, furniture and fixtures	-2,743,253	-3,256,632	-350,539
Additions to patent rights	-420,333	-244,761	-231,260
Net cash used in investing activities	-293,121	-21,667,632	-15,605,780
Cash flows from financing activities:	'	'	'
Proceeds from issuance of common stock, net	0	53,328,188	21,280,718
Proceeds from exercise of warrants and stock options	2,326,838	11,579,413	6,020,436
Taxes paid from net share settlement of equity awards	-104,329	-28,916	-233,291
Net cash provided by financing activities	2,222,509	64,878,685	27,067,863
Effect of exchange rate changes on cash and cash equivalents	8,935	1,067	-25,957
Net increase (decrease) in cash and cash equivalents	-13,029,828	32,739,132	9,510,119
Cash and cash equivalents:	'	'	'
Beginning of year	52,097,064	19,357,932	9,847,813
End of year	39,067,236	52,097,064	19,357,932
Noncash investing activities:	'	'	'
Purchases of equipment, molds, furniture and fixtures recorded in accounts payable and accrued expenses	$985,365	$0	$0

Description_of_Business

Description of Business	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Description of Business	'
	1	Description of Business
	Antares Pharma, Inc. (the “Company” or “Antares”) is an emerging specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company has numerous partnerships with pharmaceutical companies as well as multiple internal product development programs. The Company has developed both subcutaneous and intramuscular injection technology systems which include Vibex® disposable pressure-assisted auto injectors, reusable needle-free injectors, and disposable multi-use pen injectors.
	On October 14, 2013, the Company announced the approval of OTREXUP™ (methotrexate) injection by the FDA, and in January 2014 announced the product launch of OTREXUP™. OTREXUP™ is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. OTREXUP™ is indicated for adults with severe active rheumatoid arthritis (“RA”) or children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. The Company has worldwide marketing rights for OTREXUP™. The Company will commercialize OTREXUP™ in the U.S. for the treatment of RA and has provided LEO Pharma the exclusive right to commercialize OTREXUP™ in the U.S. for the treatment of psoriasis.
	The Company is also developing Vibex® QS T for testosterone replacement therapy for men suffering from symptomatic testosterone deficiency. In February 2014 the Company announced positive top line results from a clinical study evaluating the PK of testosterone enanthate administered weekly by subcutaneous injection at doses of 50 mg and 100 mg via the VIBEX® QS T auto injector device in hypogonadal adult males. The study enrolled 39 patients at nine investigative sites in the United States. The results are considered positive in that Vibex® QS T treatment resulted in most patients achieving average levels of testosterone within the normal range from the first dose onward. Vibex® QS T was also safe and well tolerated by all dosed patients. The Company intends to begin a Phase 3 clinical study in 2014 to validate the results in a larger group of hypogonadal men over an extended period of at-home weekly dosing.
	The Company has licensed its reusable needle-free injection device for use with human growth hormone (“hGH”) to Teva Pharmaceutical Industries, Ltd. (“Teva”), Ferring Pharmaceuticals BV (“Ferring”) and JCR Pharmaceuticals Co., Ltd. (“JCR”), with Teva and Ferring being two of the Company’s primary customers. The Company’s needle-free injection device is marketed by Teva as the Tjet® injector system to administer their 5mg Tev-Tropin® brand hGH marketed in the U.S. The Company’s needle-free injection device is marketed by Ferring with their 4mg and 10mg hGH formulations as Zomajet® 2 Vision and Zomajet® Vision X, respectively, in Europe and Asia. The Company has also licensed both disposable auto and pen injection devices to Teva for use in certain fields and territories and is engaged in product development activities for Teva utilizing these devices.
	The Company also has a portfolio of gel-based products. The Company announced with Actavis on April 26, 2012, the launch of Gelnique 3%™, the Company’s topical oxybutynin gel product for the treatment of overactive bladder (“OAB”), which was approved by the FDA in December 2011. The Company has a licensing agreement with Actavis under which Actavis is currently marketing Gelnique 3%™ in the U.S. In January 2012, the Company entered into a licensing agreement with Daewoong Pharmaceuticals under which Daewoong will commercialize this product, once approved in South Korea. The Company’s gel portfolio also includes Elestrin® (estradiol gel) currently marketed by Meda Pharma in the U.S. for the treatment of moderate-to-severe vasomotor symptoms associated with menopause.
	The Company has two facilities in the U.S. The Parenteral Products Group located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company’s reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted auto injector and pen injector systems. The Company’s corporate head office, Product Development Group and Commercial Group are located in Ewing, New Jersey, where the Product Development Group directs the clinical, regulatory and commercial development of the Company’s internal drug/device combination products. Our Commercial Group is responsible for sales, marketing, medical affairs, trade and third party reimbursement for our internally developed products.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	2	Summary of Significant Accounting Policies
	Basis of Presentation
	The accompanying consolidated financial statements include the accounts of Antares Pharma, Inc. and its three wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
	Certain prior year amounts have been reclassified in the consolidated financial statements to conform to the current year presentation. These reclassifications were made to present sales and marketing as a separate line item as the Company commences commercialization of OTREXUP™. Business development expenses previously included within sales, marketing and business development have been reclassified to general and administrative expense. These reclassifications had no effect on previously reported net income or total operating expenses.
	Use of Estimates
	The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s significant accounting estimates relate to the revenue recognition periods for license revenues, product warranty accruals and determination of the fair value and recoverability of goodwill and patent rights. Actual results could differ from these estimates.
	Foreign Currency Translation
	The majority of the foreign subsidiaries revenues are denominated in U.S. dollars, and any required funding of the subsidiaries is provided by the U.S. parent. Nearly all operating expenses of the foreign subsidiaries, including labor, materials, leasing arrangements and other operating costs, are denominated in Swiss Francs. Additionally, bank accounts held by foreign subsidiaries are denominated in Swiss Francs, there is a low volume of intercompany transactions and there is not an extensive interrelationship between the operations of the subsidiaries and the parent company. As such, the Company has determined that the Swiss Franc is the functional currency for its foreign subsidiaries. The reporting currency for the Company is the United States Dollar (“USD”). The financial statements of the Company’s foreign subsidiaries are translated into USD for consolidation purposes. All assets and liabilities are translated using period-end exchange rates and statements of operations items are translated using average exchange rates for the period. The resulting translation adjustments are recorded as a separate component of stockholders’ equity, comprising all of the accumulated other comprehensive income (loss). Sales to certain customers by the U.S. parent are in currencies other than the U.S. dollar and are subject to foreign currency exchange rate fluctuations. Foreign currency transaction gains and losses are included in foreign exchange gain (loss) in the consolidated statements of operations.
	Cash Equivalents
	The Company considers highly liquid debt instruments with original maturities of 90 days or less to be cash equivalents.
	Allowance for Doubtful Accounts
	Trade accounts receivable are stated at the amount the Company expects to collect. The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. The Company considers the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. The Company’s accounts receivable balance is typically due from its large pharmaceutical customers such as Teva and Ferring, and at December 31, 2013, over 95% of the accounts receivable balance was due from these organizations. These companies have historically paid timely and have been financially stable organizations. Due to the nature of the accounts receivable balance, the Company believes the risk of doubtful accounts is minimal. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required. The Company provides for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. Balances that remain outstanding after the Company has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable. The Company recorded no bad debt expense in each of the last three years. The allowance for doubtful accounts balance was $10,000 at December 31, 2013 and 2012.
	Inventories
	Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. Certain components of the Company’s products are provided by a limited number of vendors, and the Company’s production and assembly operations are outsourced to third-party suppliers where substantially all of the Company’s inventory is located. Disruption of supply from key vendors or third-party suppliers may have a material adverse impact on the Company’s operations.
	Equipment, Molds, Furniture, and Fixtures
	Equipment, molds, furniture, and fixtures are stated at cost and are depreciated using the straight-line method over their estimated useful lives ranging from three to ten years. Depreciation expense was $359,471, $145,775 and $86,636 for the years ended December 31, 2013, 2012 and 2011, respectively.
	Goodwill
	The Company has $1,095,355 of goodwill recorded as of December 31, 2013 that relates to the Minnesota reporting unit. The Company evaluates the carrying amount of goodwill on December 31 of each year and between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of the Minnesota reporting unit below its carrying amount. Such circumstances could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, (3) an adverse action or assessment by a regulator, or (4) a sustained significant drop in the Company’s stock price. When evaluating whether goodwill is impaired, the Company compares the fair value of the Minnesota reporting unit to the carrying amount, including goodwill. If the carrying amount of the Minnesota reporting unit exceeded its fair value, then the amount of the impairment loss would be measured. The impairment loss would be calculated by comparing the implied fair value of goodwill to its carrying amount. In calculating the implied fair value of goodwill, the fair value of the Minnesota reporting unit would be allocated to all of its other assets and liabilities based on their fair values. The excess of the fair value of the Minnesota reporting unit over the amount assigned to its other assets and liabilities is the implied fair value of goodwill. An impairment loss would be recognized when the carrying amount of goodwill exceeds its implied fair value.
	In evaluating whether the fair value of the Minnesota reporting unit was below its carrying amount, the Company used the market capitalization of the Company at December 31, 2013, which was approximately $575 million, to calculate an estimate of fair value of the Minnesota reporting unit. The Company determined that the percentage of the total market capitalization of the Company at December 31, 2013 attributable to the Minnesota reporting unit would have to be unreasonably low before the fair value of the Minnesota reporting unit would be less than its carrying amount. In making this determination, the Company evaluated the activity at the Minnesota reporting unit compared to the total Company activity, and considered the source and potential value of agreements currently in place, the source of recent product sales and development revenue growth, the source of total Company revenue and the source of cash generating activities. After performing the market capitalization analysis and concluding that the fair value of the Minnesota reporting unit was not below its carrying amount, the Company determined that no further detailed determination of fair value was required.
	The Company’s evaluation of goodwill resulted in no impairment losses in 2013, 2012 and 2011.
	Patent Rights
	The Company capitalizes the cost of obtaining and defending patent rights when there are projected future cash flows for marketed or partnered products associated with the patent. These capitalized costs are being amortized on a straight-line basis over periods ranging from five to fifteen years beginning on the earlier of the date the patent is issued or the first commercial sale of product utilizing such patent rights. Amortization expense for the years ended December 31, 2013, 2012 and 2011 was $133,788, $85,253 and $81,535, respectively, and is recorded in general and administrative expenses in the consolidated statements of operations.
	Impairment of Long-Lived Assets and Long-Lived Assets to Be Disposed Of
	Long-lived assets, including patent rights, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset or asset group. This analysis can be very subjective as the Company relies upon signed distribution or license agreements with variable cash flows to substantiate the recoverability of long-lived assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.
	Each year the Company reviews patent costs for impairment and identifies patents related to products for which there are no signed distribution or license agreements or for which no revenues or cash flows are anticipated. In 2013, the Company recognized expense of $65,022 in connection with the write off of patent costs related to abandoned patents or patents no longer connected with current products. No impairment charges were recognized in 2012 or 2011. The gross carrying amount and accumulated amortization of patents, which are the only intangible assets of the Company subject to amortization, were $2,635,706 and $1,290,529, respectively, at December 31, 2013 and were $2,244,086 and $1,120,434, respectively, at December 31, 2012. The Company’s estimated aggregate patent amortization expense for the next five years is approximately $145,000, $152,000, $160,000, $160,000 and $160,000 in 2014, 2015, 2016, 2017 and 2018, respectively.
	Fair Value of Financial Instruments
	Cash and cash equivalents are stated at cost, which approximates fair value.
	All short-term and long-term investments are U.S. Treasury bills or U.S. Treasury notes that are classified as held-to-maturity because the Company has the positive intent and ability to hold the securities to maturity. The securities are carried at their amortized cost. The fair value of all securities is determined by quoted market prices, which is a Level 1 fair value measurement. All long-term investments mature in less than two years. At December 31, 2013 the short-term investments had a fair value of $24,021,522 and a carrying value of $24,014,305 and the long-term investments had a fair value of $6,007,851 and a carrying value of $6,008,169. At December 31, 2012 the short-term investments had a fair value of $21,116,952 and a carrying value of $21,112,623 and the long-term investments had a fair value of $12,016,530 and a carrying value of $12,015,906.
	Revenue Recognition
	The Company recognizes revenue from the sale of products and from license fees, milestones and royalties. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred and title has passed, (iii) the price is fixed or determinable and (iv) collectability is reasonably assured.
	The Company sells its proprietary reusable needle-free injectors and related disposable products to pharmaceutical partners and through medical product distributors. The Company’s reusable injectors and related disposable products are not interchangeable with any competitive products and must be used together. The Company recognizes revenue upon shipment when title transfers. The Company offers no price protection or return rights other than for customary warranty claims. Sales terms and pricing are governed by license and distribution agreements.
	Revenue arrangements with multiple deliverables are divided into separate units of accounting if certain criteria are met, including whether the deliverable has stand-alone value to the customer, the customer has a general right of return relative to the delivered item and delivery or performance of the undelivered item is probable and substantially within the vendor’s control. Arrangement consideration is allocated at the inception of the arrangement to all deliverables on the basis of their relative selling price. The selling price for each deliverable is determined using: (i) vendor-specific objective evidence of selling price (VSOE), if it exists, (ii) third-party evidence of selling price (TPE) if VSOE does not exist, and (iii) the Company’s best estimate of the selling price if neither VSOE nor TPE exists. For transactions entered into prior to January 1, 2011, revenue is recognized for each deliverable based upon the applicable revenue recognition criteria discussed above and upon acceptance of goods or performance of service. Effective January 1, 2011, for new or significantly modified transactions, the Company allocates revenue consideration, excluding contingent consideration, based on the relative selling prices of the separate units of accounting contained within an arrangement containing multiple deliverables.
	Royalty revenues are recognized in the quarter earned when the Company has information available to determine the royalty amount, however, the majority of the Company’s royalty revenues are recognized one quarter in arrears as information is typically not available to determine quarterly royalty earnings until royalty statements are received from partners.
	At December 31, 2013, $6,386,416 of non-refundable cash payments received have been recorded as deferred revenue in cases where the revenue is not immediately recognized due to the earnings process not yet having been completed.
	Shipping and Handling Costs
	The Company records shipping and handling costs in cost of product sales.
	Stock-Based Compensation
	The Company records compensation expense associated with share based awards granted to employees at the fair value of the award on the date of grant. The expense is recognized over the period during which an employee is required to provide services in exchange for the award. The Company uses the Black-Scholes option valuation model to determine the fair value of stock options. The fair value model includes various assumptions, including the expected volatility and expected life of the awards.
	Product Warranty
	The Company provides a warranty on its reusable needle-free injector devices. Warranty terms for these devices sold to end-users by dealers and distributors are included in the device instruction manual included with each device sold. Warranty terms for these devices sold to pharmaceutical partners who provide their own warranty terms to end-users are included in the contracts with the pharmaceutical partners. The Company is obligated to repair or replace, at the Company’s option, a needle-free injector device found to be defective due to use of defective materials or faulty workmanship. The warranty does not apply to any product that has been used in violation of instructions as to the use of the product or to any product that has been neglected, altered, abused or used for a purpose other than the one for which it was manufactured. The warranty also does not apply to any damage or defect caused by unauthorized repair or the use of unauthorized parts. The warranty period on a needle-free injector device is typically 24 months from either the date of retail sale of the device by a dealer or distributor or the date of shipment to a customer if specified by contract. The Company recognizes the estimated cost of warranty obligations at the time the products are shipped based on historical claims incurred by the Company. The Company increased the warranty liability in 2011 due to an increase in product sales. Actual warranty claim costs could differ from these estimates. Warranty liability activity is as follows:
			Balance at		Provisions		Claims			Balance at
			Beginning of							End of
			Year							Year
	2013		$	100,000	$	50,819	$	(50,819	)	$	100,000
	2012		$	100,000	$	72,893	$	(72,893	)	$	100,000
	2011		$	20,000	$	95,766	$	(15,766	)	$	100,000
	Research and Development
	Research and development costs are expensed as incurred.
	Income Taxes
	Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. As of December 31, 2012, a valuation allowance was established to offset all of the Company’s deferred tax assets, and as of December 31, 2013, a valuation allowance was established to offset all of the U.S. deferred tax assets. For the year ended December 31, 2013, the Company recorded an income tax benefit of $300,000 after releasing $300,000 of the valuation allowance related to the Switzerland deferred tax assets.
	Net Loss Per Share
	Basic net loss per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed similar to basic net loss per share except that the weighted average shares outstanding are increased to include additional shares from the assumed exercise of stock options and warrants, if dilutive. The number of additional shares is calculated by assuming that outstanding stock options or warrants were exercised and that the proceeds from such exercise were used to acquire shares of common stock at the average market price during the reporting period. All potentially dilutive common shares were excluded from the calculation because they were anti-dilutive for all periods presented. Potentially dilutive securities at December 31, 2013, 2012 and 2011, excluded from dilutive loss per share as their effect is anti-dilutive, are as follows:
			2013		2012		2011
	Stock options and warrants			8,242,992		10,830,530		17,860,956

Composition_of_Certain_Financi

Composition of Certain Financial Statement Captions	12 Months Ended
	Dec. 31, 2013
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Composition of Certain Financial Statement Captions	'
	3	Composition of Certain Financial Statement Captions
			December 31,			December 31,
			2013			2012
	Inventories:
	Raw material		$	1,056,054		$	609,016
	Work in process			3,034,321			—
	Finished goods			2,370,676			393,687
			$	6,461,051		$	1,002,703
	Equipment, molds, furniture and fixtures:
	Furniture, fixtures and office equipment		$	1,501,612		$	1,133,925
	Production molds and equipment			7,389,062			1,503,615
	Molds and tooling in process			424,521			2,948,249
	Less accumulated depreciation			(2,362,944	)		(2,002,685	)
			$	6,952,251		$	3,583,104
	Patent rights:
	Patent rights		$	2,635,706		$	2,244,086
	Less accumulated amortization			(1,290,529	)		(1,120,434	)
			$	1,345,177		$	1,123,652
	Accrued expenses and other liabilities:
	Accrued employee compensation and benefits		$	2,348,456		$	1,896,832
	Liabilities related to OTREXUP™ development and commercialization expenses			1,946,869			—
	Other liabilities			1,157,750			1,019,868
			$	5,453,075		$	2,916,700

Leases

Leases	12 Months Ended
	Dec. 31, 2013
Leases [Abstract]	'
Leases	'
	4	Leases
	The Company has non-cancelable operating leases for its corporate headquarters facility in Ewing, New Jersey, and its office, research and development facility in Plymouth, MN, a suburb of Minneapolis, MN. In November 2013, the Company exercised an early termination option under which the Company must exit the current Plymouth location by August 31, 2014. In December 2013, the Company entered into a lease agreement for approximately 18,000 square feet of office, research and development space in a new Plymouth location, which is expected to be ready for occupancy in April 2014. The leases require payment of all executory costs such as maintenance and property taxes. The Company also leases certain equipment under various operating leases. Rent expense, net, incurred for the years ended December 31, 2013, 2012 and 2011 was $453,142, $325,971 and $261,171, respectively. Future minimum lease payments under operating leases with remaining terms in excess of one year as of December 31, 2013 were as follows:
			Amount
	2014		$	372,767
	2015			569,967
	2016			581,377
	2017			592,905
	2018			604,554
	Thereafter			1,037,921
	Total future minimum lease payments		$	3,759,491

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	5	Income Taxes
	The Company was subject to taxes in both the U.S. and Switzerland in each of the years in the three-year period ended December 31, 2013. In the U.S., the Company incurred losses for both book and tax purposes for the year ended December 31, 2013, and, accordingly, no income taxes were provided. In Switzerland, net operating loss carryforwards were used to fully offset taxable income of approximately $500,000 and $5,500,000 in the years ended December 31, 2013 and 2012, respectively, and no income taxes were provided.
	Income (loss) before income taxes was derived from the following jurisdictions:
			2013			2012			2011
	U.S.		$	(21,568,727	)	$	(16,477,710	)	$	(3,977,263	)
	Switzerland			761,951			5,050,260			(410,657	)
			$	(20,806,776	)	$	(11,427,450	)	$	(4,387,920	)
	Effective tax rates differ from statutory income tax rates in the years ended December 31, 2013, 2012 and 2011 as follows:
			2013			2012			2011
	Statutory income tax rate			(34.0	)%		(34.0	)%		(34.0	)%
	State income taxes			(1.0	)		(3.6	)		(1.6	)
	Valuation allowance increase (decrease)			28.8			29.8			(4.3	)
	Effect of foreign operations			(0.7	)		(8.5	)		1.9
	Change in unused net operating loss and credit carryforwards			(1.0	)		14			35.5
	Nondeductible items			6.5			0.6			1.8
	Other			—			1.7			0.7
				(1.4	)%		0	%		0	%
	Deferred tax assets (liabilities) as of December 31, 2013 and 2012 consist of the following:
			2013			2012
	Net operating loss carryforward – U.S.		$	28,832,000		$	22,411,000
	Net operating loss carryforward – Switzerland			4,556,000			5,551,000
	Research and development tax credit carryforward			2,589,000			1,292,000
	Deferred revenue			320,000			398,000
	Depreciation and amortization			(105,000	)		115,000
	Stock-based compensation			1,581,000			1,573,000
	Other			93,000			1,150,000
				37,866,000			32,490,000
	Less valuation allowance			(37,566,000	)		(32,490,000	)
			$	300,000		$	—
	The valuation allowance for deferred tax assets as of December 31, 2013 and 2012 was $37,566,000 and $32,490,000, respectively. The total valuation allowance increased $5,076,000 for the year ended December 31, 2013 and increased $3,579,000 for the year ended December 31, 2012. Prior to 2012, management determined that it was more likely than not that the deferred tax assets associated with the NOL carryforwards in Switzerland would not be realized and provided a valuation allowance for the full amount of the deferred tax assets. In 2013 and 2012, the Company realized the benefit of the deferred tax assets associated with approximately $500,000 and $5,500,000, respectively, of NOL carryforwards in Switzerland for which a valuation allowance had been recorded. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences become deductible or in which net operating loss or tax credit carryforwards can be utilized. Both positive and negative evidence is considered in assessing the realizability of deferred tax assets and determining whether or not to record a valuation allowance. After considering that the Switzerland operations had generated taxable income for two consecutive years and after determining that it appears likely that taxable income will continue, in the fourth quarter of 2013 management determined it is more likely than not that a portion of the deferred tax assets will be realized; therefore, $300,000 of the valuation allowance has been released as of December 31, 2013. After considering the evidence with respect to the U.S. deferred tax assets, management determined that as of December 31, 2013, it continues to be more likely than not that the U.S. deferred tax assets will not be realized and has recorded a valuation allowance against all U.S. deferred tax assets.
	The Company has a U.S. federal net operating loss carryforward at December 31, 2013, of approximately $87,100,000, which, subject to limitations of Internal Revenue Code (“IRC”) Section 382, is available to reduce income taxes payable in future years. If not used, this carryforward will expire in years 2018 through 2033. Included in the federal net operating loss is approximately $5,200,000 of loss generated by deductions related to equity-based compensation, the tax effect of which will be recorded to additional paid in capital when utilized. Additionally, the Company has a research credit carryforward of approximately $2,600,000. These credits expire in years 2018 through 2033.
	Utilization of U.S. net operating losses and tax credits of the Company may be subject to annual limitations under IRC Sections 382 and 383, respectively. The annual limitations, if any, have not yet been determined. When a review is performed and if any annual limitations are determined, then the gross deferred tax assets for the net operating losses and tax credits would be reduced with a reduction in the valuation allowance of a like amount.
	The Company also has a Swiss net operating loss carryforward at December 31, 2013, of approximately $33,700,000, which is available to reduce income taxes payable in future years. If not used, this carryforward will expire in years 2014 through 2018, with approximately $33,300,000 expiring over the next three years.
	As of December 31, 2013 and 2012, there were no unrecognized tax benefits. Accordingly, a tabular reconciliation from beginning to ending periods is not provided. The Company will classify any future interest and penalties as a component of income tax expense if incurred. To date, there have been no interest or penalties charged or accrued in relation to unrecognized tax benefits.
	The Company does not anticipate that the total amount of unrecognized tax benefits will change significantly in the next twelve months.
	The Company is subject to federal and state examinations for the years 2008 and thereafter. There are no tax examinations currently in progress.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Stockholders' Equity	'
	6	Stockholders’ Equity
	Common Stock
	In October 2012, the Company sold 12,500,000 shares of common stock at a price of $4.00 per share in a public offering, and in November 2012 the Company sold 1,759,868 shares of the Company’s common stock at $4.00 per share as a result of the partial exercise of the underwriters’ over-allotment option. The Common Stock sales resulted in net proceeds of $53,328,188 after deducting offering expenses of $3,711,284.
	Stock Options
	The Company’s 2008 Equity Compensation Plan (the “Plan”) allows for grants in the form of incentive stock options, nonqualified stock options, stock units, stock awards, stock appreciation rights, and other stock-based awards. All of the Company’s officers, directors, employees, consultants and advisors are eligible to receive grants under the Plan. Under the Plan, the maximum number of shares authorized for issuance is 15,000,000 and the maximum number of shares of stock that may be granted to any one participant during a calendar year is 1,000,000 shares. Options to purchase shares of common stock are granted at exercise prices not less than 100% of fair market value on the dates of grant. The term of each option is either 10 or 11 years and the options vest in varying periods. As of December 31, 2013, the Plan had 247,400 shares available for grant. Stock option exercises are satisfied through the issuance of new shares.
	A summary of stock option activity under the Plan as of December 31, 2013 and the changes during the three years then ended is as follows:
			Number of			Weighted			Weighted			Aggregate
			Shares			Average			Average			Intrinsic
						Exercise			Remaining			Value
						Price			Contractual			($)
						($)			Term (Years)
	Outstanding at December 31, 2010			7,657,876			1.18
	Granted/Issued			972,409			1.75
	Exercised			(750,063	)		1.37						488,724
	Cancelled/Forfeited			(94,550	)		3.21
	Outstanding at December 31, 2011			7,785,672			1.21
	Granted/Issued			1,334,731			3.18
	Exercised			(1,164,636	)		1.2						2,620,360
	Cancelled/Forfeited			(141,206	)		4.06
	Outstanding at December 31, 2012			7,814,561			1.49
	Granted/Issued			1,129,380			3.99
	Exercised			(981,385	)		0.72						3,319,471
	Cancelled/Forfeited			(264,664	)		3.48
	Outstanding at December 31, 2013			7,697,892			1.89			6.3			19,883,523
	Exercisable at December 31, 2013			6,207,584			1.47			5.6			18,605,127
	As of December 31, 2013, there was approximately $2,549,656 of total unrecognized compensation cost related to nonvested outstanding stock options that is expected to be recognized over a weighted average period of approximately 2.2 years.
	Stock option expense recognized in 2013, 2012 and 2011 was approximately $1,364,000, $1,164,000 and $1,055,000, respectively. The per share weighted average fair value of options granted during 2013, 2012 and 2011 was estimated as $2.26, $1.64, $0.89, respectively, on the date of grant using the Black-Scholes option pricing model based on the assumptions noted in the table below. Expected volatilities are based on the historical volatility of the Company’s stock. The weighted average expected life is based on both historical and anticipated employee behavior.
			December 31,
			2013			2012			2011
	Risk-free interest rate			0.9	%		0.7	%		1.7	%
	Annualized volatility			62	%		61	%		59	%
	Weighted average expected life, in years			6			5			5
	Expected dividend yield			0	%		0	%		0	%
	Option exercises during 2013, 2012 and 2011 resulted in proceeds of $692,348, $792,203 and $1,025,985, respectively, and in the issuance of 981,385, 965,597 and 750,063 shares of common stock, respectively. In 2012, 583,344 options were exercised under a cashless provision resulting in the issuance of 384,305 shares of common stock and no cash proceeds to the Company.
	Warrants
	Warrant activity is summarized as follows:
			Number of			Weighted
			Shares			Average Price ($)
	Outstanding at December 31, 2010			17,685,059			1.56
	Exercised			(4,107,759	)		1.37
	Cancelled			(3,502,016	)		1.5
	Outstanding at December 31, 2011			10,075,284			1.66
	Exercised			(7,056,075	)		1.53
	Cancelled			(3,240	)		2
	Outstanding at December 31, 2012			3,015,969			1.98
	Exercised			(1,470,869	)		1.11
	Cancelled			(1,000,000	)		3.78
	Outstanding at December 31, 2013			545,100			1
	Warrant exercises during 2013, 2012 and 2011 resulted in proceeds of $1,634,490, $10,787,210 and $4,994,451, respectively, and in the issuance of 1,470,869, 7,056,075 and 3,725,272 shares of common stock, respectively.
	Stock Awards
	The employment agreements with certain members of executive management included performance-based incentives under which the executives could be awarded shares of common stock upon the occurrence of various triggering events. As of December 31, 2013, the time period for these potential awards had expired. There were 35,000 and 145,454 shares awarded under these agreements in 2012, and 2011, respectively.
	At times, the Company makes discretionary grants of its common stock to members of management and other employees in lieu of cash bonus awards or in recognition of special achievements. There were no discretionary grants of common stock in 2013, and grants in 2012 and 2011 totaled 60,000 and 368,267, respectively.
	Expense is recognized on a straight line basis over the vesting period and is based on the fair value of the stock on the grant date. The fair value of each stock award is determined based on the number of shares granted and the market price of the Company’s common stock on the date of grant. Expense recognized in connection with performance and discretionary stock awards was $8,722, $301,017 and $771,491 in 2013, 2012 and 2011, respectively.
	A portion of the shares vested in 2013, 2012 and 2011 were net-share settled such that the Company withheld shares with value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The total shares withheld were 30,153, 11,165 and 121,182 in 2013, 2012 and 2011, respectively, and were based on the value of the shares on their vesting date as determined by the Company’s closing stock price. Total payments for the employees’ tax obligations to the taxing authorities were $104,329, $28,916 and $233,291 in 2013, 2012 and 2011, respectively, and are reflected as a financing activity within the Consolidated Statements of Cash Flows. These net-share settlements had the effect of share repurchases by the Company as they reduced the number of shares that would have otherwise been issued as a result of the vesting and did not represent an expense to the Company.
	In addition to the shares granted to members of management and employees, at times directors receive a portion of their annual compensation in shares of Company common stock. Expense is recognized on a straight line basis over the one year period that the compensation is earned. Expense recognized in connection with shares granted to directors was $679,500, $560,000 and $46,500 in 2013, 2012 and 2011, respectively.
	As of December 31, 2013, a total of 212,618 shares granted to directors were unvested. As of December 31, 2013, there was approximately $350,000 of total unrecognized compensation cost related to nonvested stock awards that is expected to be recognized over a weighted average period of approximately 5 months. The weighted average fair value of the shares granted in 2013 and 2012, excluding shares granted under the LTIP program, was $4.01 and $2.84 per share, respectively.
	Long Term Incentive Program
	The Company’s Board of Directors has approved a long term incentive program for the benefit of the Company’s senior executives. Pursuant to the long term incentive program, the Company’s senior executives have been awarded stock options and performance stock units with targeted values based on values granted by the Company’s peer group. In 2013, the program was modified such that the value of the annual award for each senior executive was delivered one-third in the form of performance stock units, one-third in the form of shares of restricted stock and one-third in the form of stock options. In prior years, two thirds of the value for each senior executive was delivered in the form of stock options and one third of the value was delivered in the form of performance stock units. The stock options have a ten-year term, have an exercise price equal to the closing price of the Company’s common stock on the date of grant, vest in quarterly installments over three years, were otherwise granted on the same standard terms and conditions as other stock options granted pursuant to the Plan and are included in the stock options table above. The restricted stock vests in three equal annual installments. Expense recognized in 2013 in connection with the restricted stock was $125,000. The performance stock unit awards made to the senior executives will be vested and convert into actual shares of the Company’s common stock based on the Company’s attainment of certain performance goals over a performance period of three years. Expense recognized in 2013 in connection with the performance stock unit awards for defined performance goals considered probable of achievement was $259,000. The performance stock unit awards and restricted stock granted under the long term incentive program are summarized in the following table:
			Performance Stock Units						Restricted Stock
			Number of			Weighted			Number of			Weighted
			Shares			Average Fair			Shares			Average Fair
						Value ($)						Value ($)
	Outstanding at December 31, 2010			—			—			—			—
Granted			182,000			1.66			—			—
Vested			—			—			—			—
Forfeited/Expired			—			—			—			—
Outstanding at December 31, 2011			182,000			1.66			—			—
Granted			137,715			4.26			—			—
Vested			—			—			—			—
Forfeited/Expired			—			—			—			—
Outstanding at December 31, 2012			319,715			2.78			—			—
Granted			185,185			3.96			185,185			3.96
Vested			—			—			—			—
Forfeited/Expired			(98,237	)		3.32			(29,461	)		3.96
Outstanding at December 31, 2013			406,663			3.19			155,724			3.96

Employee_401k_Savings_Plan

Employee 401(k) Savings Plan	12 Months Ended
	Dec. 31, 2013
Compensation And Retirement Disclosure [Abstract]	'
Employee 401(k) Savings Plan	'
	7	Employee 401(k) Savings Plan
	The Company sponsors a 401(k) defined contribution retirement savings plan that covers all U.S. employees who have met minimum age and service requirements. Under the plan, eligible employees may contribute up to 50% of their annual compensation into the plan up to the IRS annual limits. At the discretion of the Board of Directors, the Company may contribute elective amounts to the plan, allocated in proportion to employee contributions to the plan, employee’s salary, or both. For the years ended December 31, 2013, 2012 and 2011, the total number of employees enrolled in the plan has increased and the Company elected to make contributions to the plan totaling approximately $230,000, $173,000 and $109,000, respectively.

License_Agreements

License Agreements	12 Months Ended
	Dec. 31, 2013
Revenue Recognition [Abstract]	'
License Agreements	'
	8	License Agreements
	LEO Pharma Promotion and License Agreement
	In November 2013 the Company entered into a promotion and license agreement with LEO Pharma (“LEO”). Under this agreement the Company granted LEO the exclusive right to promote OTREXUP™ to dermatologists for symptomatic control of severe recalcitrant psoriasis in adults in the U.S. LEO is responsible for promotion and marketing activities in dermatology and the Company is responsible for the supply of OTREXUP™ product and samples. The Company received from LEO a non-refundable upfront payment of $5.0 million, will receive a milestone payment of $5.0 million upon launch of the product and meeting other performance obligations and will receive a milestone payment of $10.0 million upon realizing a defined level of net sales in a calendar year. The Company will pay LEO a percentage of net sales generated in dermatology and will record the payments to LEO as sales and marketing expense.
	The Company identified and evaluated a number of deliverables in the agreement and concluded that none of the deliverables have value on a stand-alone basis. As a result, these deliverables do not qualify for treatment as separate units of accounting. Accordingly, the deliverables have been accounted for as a single unit of accounting and each of the payments will be allocated to these deliverables and will be recognized as revenue over the 35 month estimated life of the agreement. The Company recognized revenue of approximately $571,000 in the year ended December 31, 2013, and recorded the $4,429,000 remaining portion of the upfront payment as deferred revenue at December 31, 2013.
	Teva License Development and Supply Agreements
	In November 2012, the Company entered into a license, supply and distribution agreement with Teva for an auto injector product containing sumatriptan for the treatment of migraines. Teva will manufacture and supply sumatriptan in a prefilled syringe. The Company will manufacture the device, assemble the device and prefilled syringe and supply the final product to Teva for distribution. Teva will distribute the product in the United States. Teva also received an option for rights in other territories. Under the agreement, the Company received an upfront payment, which was deferred, and will receive a milestone payment upon commercial launch. In addition, net profits will be split 50/50 between the Company and Teva. The term of the agreement is seven years from commercial launch, with automatic one year renewals.
	In December 2007, the Company entered into a license, development and supply agreement with Teva under which the Company will develop and supply a disposable pen injector for use with two undisclosed patient-administered pharmaceutical products. Under the agreement, an upfront payment, development milestones, and royalties on Teva’s product sales, as well as a purchase price for each device sold are to be received by the Company under certain circumstances. Based on an analysis under accounting literature applicable at the time of the agreement, the entire arrangement was considered a single unit of accounting. Therefore, payments received and development costs incurred were deferred and were to be recognized from the start of manufacturing through the end of the initial contract period. In January 2011, this license, development and supply agreement was amended wherein Teva pays for all development work and tooling associated with device development. Additionally, we are now developing two different disposable pens, one for each product. As further explained in Note 9 to the consolidated financial statements, the Company determined that the changes to the agreement as a result of the amendment are a material modification to the agreement and the accounting for the revenue and costs under this agreement was changed. This agreement will continue until the later of December 2017 or the expiration date of the last to expire patent covering the device or product that is filed no later than 12 months after FDA approval, and will be automatically renewed for successive periods of two years each.
	In September 2006, the Company entered into a Supply Agreement with Teva. Pursuant to the agreement, Teva is obligated to purchase all of its needle-free delivery device requirements from Antares for hGH to be marketed in the United States. Antares was entitled to an upfront cash payment, milestone fees and royalty payments on Teva’s net sales, as well as a purchase price for each device sold. The upfront payment was recognized as revenue over the development period. The milestone fees and royalties will be recognized as revenue when earned. In 2009, Teva launched the Company’s Tjet needle-free device with their hGH Tev-Tropin®. In 2010, the Company received a milestone payment from Teva in connection with this agreement. The original term of this agreement extended through September 2013. In May 2013 the agreement was amended to provide for one year automatic renewals unless terminated by either party six months ahead of the expiring term.
	In July 2006, the Company entered into an exclusive License Development and Supply Agreement with Teva. Pursuant to the agreement, Teva is obligated to purchase all of its delivery device requirements from Antares for an auto injector product containing epinephrine to be marketed in the United States and Canada. Antares was entitled to an upfront cash payment, milestone fees, a negotiated purchase price for each device sold, as well as royalties on sales of their product. This agreement will continue until the later of July 2016 or the expiration date of the last to expire patent covering the device or product that is filed no later than 12 months after FDA approval.
	On April 26, 2012, the Company announced that Meridian Medical Technologies, a Pfizer subsidiary, entered into a settlement agreement with Teva that will resolve pending patent litigation related to its abbreviated new drug application (ANDA) for a generic epinephrine auto-injector. According to the terms of the settlement, Teva may launch a generic epinephrine auto-injector covered by its ANDA on June 22, 2015 or earlier under certain circumstances, subject to receipt of approval from the U.S. Food and Drug Administration. Additional terms of the agreement are confidential.
	Under a separate agreement, Teva has agreed to provide the Company with device orders of an undisclosed amount in the years 2013 and 2014, to make a milestone payment to the Company upon FDA approval of epinephrine auto-injector, and to assume all litigation costs related to the patent litigation between Teva and Meridian Medical.
	Ferring Agreements
	On November 6, 2009, the Company entered into an Exclusive License Agreement with Ferring, under which the Company licensed certain of its patents and agreed to transfer know-how for its transdermal gel technology for certain pharmaceutical products. This agreement had no impact on the Company’s existing licenses, the transdermal clinical pipeline, or marketed products, including Gelnique 3%™, Nestragel™ (Nestorone®), and Elestrin®. Also on November 6, 2009, in tandem with the execution of the Exclusive License Agreement, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Ferring. Pursuant to the terms and conditions of the Purchase Agreement, Ferring purchased from the Company all of the assets, including equipment, fixtures, fittings and inventory, located at the Company’s research and development facility located in Allschwil, Switzerland (the “Facility”). Further pursuant to the terms and conditions of the Purchase Agreement, Ferring assumed the contractual obligations related to the Facility, including the real property lease for the Facility, and continued to employ the employees working at the Facility. The Company also entered into a Consultancy Services Agreement with Ferring for a period of 12 months, under which the Company provided services in connection with development of certain pharmaceutical products under the Exclusive License Agreement. Under these agreements the Company received upfront license fees, payments for assets and payments for services rendered under the consultancy agreement. In addition, the Company will receive milestone payments as certain defined milestones are achieved. The agreement is effective until the last to expire patent applicable under the agreement.
	Although there were three separate agreements with Ferring, they were evaluated as a single arrangement for purposes of applying the applicable accounting standard. Payments received under the Exclusive License Agreement were recognized over the 12 month period of the Consultancy Services Agreement, as this is the period of time the Company was involved in development. Payments received in connection with milestones will be recognized when the milestone payment is received. The amount received from Ferring for the assets sold resulted in a gain, which was recorded in other income.
	The Company entered into a License Agreement, dated January 22, 2003, with Ferring, under which the Company licensed certain of its intellectual property and extended the territories available to Ferring for use of certain of the Company’s reusable needle-free injector devices. Specifically, the Company granted to Ferring an exclusive, perpetual, irrevocable, royalty-bearing license, within a prescribed manufacturing territory, to manufacture certain of the Company’s reusable needle-free injector devices for the field of human growth hormone. The Company granted to Ferring similar non-exclusive rights outside of the prescribed manufacturing territory.
	As consideration for the license grants, Ferring paid the Company an upfront payment upon execution of the License Agreement, and paid an additional milestone in 2003. Ferring also pays the Company royalties for each device manufactured by or on behalf of Ferring, including devices manufactured by the Company. These royalty obligations expire, on a country-by-country basis, when the respective patents for the products expire, despite the fact that the License Agreement does not itself expire until the last of such patents expires. The license fees have been deferred and are being recognized in income over the period from 2003 through expiration of the patents in 2016.
	In March 2007, the Company amended the agreement increasing the royalty rate and device pricing, included a next generation device and provided for payment principally in U.S. dollars rather than Euros.
	Actavis License and Commercialization Agreement
	In July 2011, the Company entered into an exclusive licensing agreement with Actavis to commercialize, in the U.S. and Canada, the Company’s topical oxybutynin gel 3% product, which was subsequently approved by the FDA in December 2011.
	Under this agreement the Company received payments for certain manufacturing start-up activities and delivery of launch quantities, and has received and is entitled to receive future royalties on both the Company’s oxybutynin gel 3% product and Actavis’ oxybutynin gel product Gelnique® 10%, and will potentially receive sales based milestone payments. The milestone payment based on the achievement of regulatory approval was subject to reimbursement to Actavis if launch quantities were not delivered within a certain defined time period. Actavis assumed all responsibility for manufacture and supply of the product in 2013. The term of the agreement ends on the later of April 2024 or the expiration date of the last to expire patent.
	Arrangement consideration has been allocated to the separate units of accounting based on the relative selling prices. Selling prices are determined using vendor specific objective evidence (“VSOE”), when available, third-party evidence (“TPE”), when available, or an estimate of selling price when neither of the first two options is available for a given unit of accounting. Selling prices in this arrangement were determined using estimated selling prices because VSOE and TPE were not available. The primary factors considered in determining selling price estimates in this arrangement were estimated costs, reasonable margin estimates and historical experience.
	The Company determined that the license and development activities, which include the manufacturing start-up activities, do not have value to the customer on a stand-alone basis as proprietary knowledge about the product and technology is required to complete the development activities. As a result, these deliverables do not qualify for treatment as separate units of accounting. Accordingly, the license and development activities have been accounted for as a single unit of accounting and arrangement consideration allocated to these deliverables was recognized as revenue over the development period, which ended upon manufacture of launch quantities. The sales based milestone payments will be recognized as revenue when earned, revenue for launch quantities was recognized when product was delivered to Actavis and royalties will be recognized as revenue when earned. The Company received a milestone payment from Actavis in December 2011 upon FDA approval, which was recorded as deferred revenue. This milestone payment was recognized as revenue in March of 2012, as launch quantities were delivered within the defined time period and the potential reimbursement liability was eliminated.
	Pfizer License Agreement
	In December 2011, the Company announced that it licensed to Pfizer Inc.’s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America. Pfizer will assume full cost and responsibility for all clinical development, manufacturing, and commercialization of the product in the licensed territory, which also includes certain non-exclusive territories outside of North America. Antares received an upfront payment, and will receive development milestones and sales based milestones, as well as royalties on net sales for three years post launch in the U.S. Because the Company has no development responsibilities, the upfront and each milestone payment will be recognized as revenue when received. Royalties will be recognized as revenue when earned.
	Daewoong Development and License Agreement
	In January 2012, the Company entered into a licensing agreement with Daewoong Pharmaceuticals (“Daewoong”) under which Daewoong will commercialize the Company’s oxybutynin gel 3% product, once approved in South Korea. The agreement terms include an upfront payment, development and sales-based milestone payments and escalating royalties based on product sales in South Korea. Because the Company has no development responsibilities, the upfront and each milestone payment will be recognized as revenue when received. Royalties will be recognized as revenue when earned. The term of the agreement ends on the later of fifteen years following launch of the product or the expiration date of the last to expire patent.
	ANI License Agreement (formerly BioSante)
	In June 2000, the Company entered into an exclusive agreement to license four applications of its drug-delivery technology to ANI Pharmaceuticals (formerly BioSante Pharmaceuticals) in the United States, Canada, China, Australia, New Zealand, South Africa, Israel, Mexico, Malaysia and Indonesia (collectively, “the ANI Territories”). ANI will use the licensed technology for the development of hormone replacement therapy products. At the signing of the contract, ANI made an upfront payment to the Company, a portion of which, per the terms of the contract, was used to partially offset a later payment made to the Company as a result of an upfront payment received by ANI under a sublicense agreement. The initial upfront payment received by the Company was for the delivery of intellectual property to ANI. The term of the agreement ends on the later of the tenth anniversary of the first commercial sale of a product or the expiration date of the last to expire patent.
	The Company will receive payments upon the achievement of certain milestones and will receive from ANI a royalty from the sale of licensed products. The Company will also receive a portion of any sublicense fees received by ANI.
	In December 2009, ANI entered into a license agreement with Azur Pharma International II Limited (“Azur”), for Elestrin®. ANI has received payments from Azur which triggered sublicense payments to the Company. Because final regulatory approval for this product was obtained by ANI and Antares had no further obligations in connection with this product, the sublicense payments were recognized as revenue when received. Elestrin® is being marketed in the U.S. by Meda Pharma, who acquired the women’s health business from Jazz Pharmaceuticals (“Jazz”), who had previously acquired Azur. The Company has received royalties on sales of Elestrin®, which have been recognized as revenue when received.

Revenue_Recognition

Revenue Recognition	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Revenue Recognition	'
	9	Revenue Recognition
	In January of 2011, the Company amended the license, development and supply agreement with Teva originally entered into in December of 2007 under which the Company will develop and supply a disposable pen injector for use with two undisclosed patient-administered pharmaceutical products. Under the original agreement, an upfront payment, development milestones, and royalties on Teva’s product sales, as well as a purchase price for each device sold were to be received by the Company under certain circumstances. Based on an analysis under accounting literature applicable at the time of the agreement, the entire arrangement was considered a single unit of accounting. Therefore, payments received and development costs incurred were deferred and were to be recognized from the start of manufacturing through the end of the initial contract period. Changes to the original agreement as a result of the amendment included the following: (i) Teva will pay for future device development activities, (ii) Teva will pay for and own all commercial tooling developed and produced under the agreement, and (iii) certain potential milestone payments were eliminated. The Company has determined that the changes to the agreement as a result of the amendment are a material modification to the agreement. Because the agreement was materially modified, the accounting was re-evaluated under the applicable current revenue recognition accounting standards. The re-evaluation resulted in the agreement being separated into multiple units of accounting and resulted in changes to both the method of revenue recognition and the period over which revenue will be recognized. The provisions of the current standards are to be applied as if they were applicable from inception of the agreement. Under the new accounting, the original license fee received will be recognized as revenue over the development period, the development milestone payments previously received were recognized as revenue immediately and revenue during the manufacturing period will be recognized as devices are sold and royalties are earned. For the year ended December 31, 2012, the accounting change resulting from the material modification resulted in recognition of licensing revenue previously deferred of $62,225, and for the year ended December 31, 2011, the accounting change resulting from the material modification resulted in recognition of development and licensing revenue previously deferred of $304,600 and $337,776, respectively, and recognition of costs previously deferred of $408,250.

Segment_Information_and_Signif

Segment Information and Significant Customers	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Segment Information and Significant Customers	'
	10	Segment Information and Significant Customers
	The Company has one operating segment, drug delivery, which includes the development of injection devices and injection based pharmaceutical products as well as transdermal gel products.
	Revenues by customer location are summarized as follows:
			For the Years Ended December 31,
			2013		2012		2011
	United States of America		$	16,479,855	$	16,964,635	$	10,236,304
	Europe			3,901,422		4,936,981		5,765,909
	Other			237,223		673,962		456,279
			$	20,618,500	$	22,575,578	$	16,458,492
	Revenues by product type:
			For the Years Ended December 31,
			2013		2012		2011
	Injection devices and supplies		$	18,156,217	$	12,642,537	$	14,360,078
	Transdermal gel products			2,462,283		9,933,041		2,098,414
			$	20,618,500	$	22,575,578	$	16,458,492
	The following summarizes significant customers comprising 10% or more of total revenue for the years ended December 31:
			2013		2012		2011
	Teva		$	13,559,541	$	7,495,978	$	8,175,990
	Ferring			3,827,098		4,933,369		5,764,208
	Actavis			1,489,942		6,770,635		1,024,240
	The following summarizes significant customers comprising 10% or more of outstanding accounts receivable as of December 31:
			2013		2012
	Teva		$	436,632	$	1,033,203
	Ferring			562,576		622,885
	Actavis			—		522,807

Quarterly_Financial_Data_unaud

Quarterly Financial Data (unaudited)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Data (unaudited)	'
	11	Quarterly Financial Data (unaudited)
			First			Second			Third			Fourth
	2013:00:00
	Total revenues (1)		$	4,528,222		$	5,837,544		$	5,507,824		$	4,744,910
	Gross profit (1)			2,501,079			2,356,862			2,503,222			4,060,107
	Net loss			(3,408,448	)		(5,103,256	)		(6,359,957	)		(5,635,115	)
	Net loss per common share (2)			(0.03	)		(0.04	)		(0.05	)		(0.04	)
	Weighted average shares			126,106,713			126,462,677			127,162,064			127,835,641
	2012:00:00
	Total revenues		$	6,864,542		$	4,523,942		$	5,685,917		$	5,501,177
	Gross profit			4,873,711			1,992,831			2,389,428			3,799,136
	Net loss			(74,394	)		(2,807,072	)		(3,534,239	)		(5,011,745	)
	Net loss per common share (2)			(0.00	)		(0.03	)		(0.03	)		(0.04	)
	Weighted average shares			103,658,571			104,551,742			108,961,792			123,436,025
	-1	Total revenues in the fourth quarter of 2013 included over $1.1 million more licensing and royalty revenue than in each of the prior three quarters, resulting in a higher gross profit as there were no associated costs with these revenues. Also impacting gross profit in the fourth quarter was development revenue having a higher gross profit than development revenue in prior quarters.
	-2	Net loss per common share is computed based upon the weighted average number of shares outstanding during each period. Basic and diluted loss per share amounts are identical as the effect of potential common shares is anti-dilutive.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying consolidated financial statements include the accounts of Antares Pharma, Inc. and its three wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
	Certain prior year amounts have been reclassified in the consolidated financial statements to conform to the current year presentation. These reclassifications were made to present sales and marketing as a separate line item as the Company commences commercialization of OTREXUP™. Business development expenses previously included within sales, marketing and business development have been reclassified to general and administrative expense. These reclassifications had no effect on previously reported net income or total operating expenses.
Use of Estimates	'
	Use of Estimates
	The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s significant accounting estimates relate to the revenue recognition periods for license revenues, product warranty accruals and determination of the fair value and recoverability of goodwill and patent rights. Actual results could differ from these estimates.
Foreign Currency Translation	'
	Foreign Currency Translation
	The majority of the foreign subsidiaries revenues are denominated in U.S. dollars, and any required funding of the subsidiaries is provided by the U.S. parent. Nearly all operating expenses of the foreign subsidiaries, including labor, materials, leasing arrangements and other operating costs, are denominated in Swiss Francs. Additionally, bank accounts held by foreign subsidiaries are denominated in Swiss Francs, there is a low volume of intercompany transactions and there is not an extensive interrelationship between the operations of the subsidiaries and the parent company. As such, the Company has determined that the Swiss Franc is the functional currency for its foreign subsidiaries. The reporting currency for the Company is the United States Dollar (“USD”). The financial statements of the Company’s foreign subsidiaries are translated into USD for consolidation purposes. All assets and liabilities are translated using period-end exchange rates and statements of operations items are translated using average exchange rates for the period. The resulting translation adjustments are recorded as a separate component of stockholders’ equity, comprising all of the accumulated other comprehensive income (loss). Sales to certain customers by the U.S. parent are in currencies other than the U.S. dollar and are subject to foreign currency exchange rate fluctuations. Foreign currency transaction gains and losses are included in foreign exchange gain (loss) in the consolidated statements of operations.
Cash Equivalents	'
	Cash Equivalents
	The Company considers highly liquid debt instruments with original maturities of 90 days or less to be cash equivalents.
Allowance for Doubtful Accounts	'
	Allowance for Doubtful Accounts
	Trade accounts receivable are stated at the amount the Company expects to collect. The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. The Company considers the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. The Company’s accounts receivable balance is typically due from its large pharmaceutical customers such as Teva and Ferring, and at December 31, 2013, over 95% of the accounts receivable balance was due from these organizations. These companies have historically paid timely and have been financially stable organizations. Due to the nature of the accounts receivable balance, the Company believes the risk of doubtful accounts is minimal. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required. The Company provides for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. Balances that remain outstanding after the Company has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable. The Company recorded no bad debt expense in each of the last three years. The allowance for doubtful accounts balance was $10,000 at December 31, 2013 and 2012.
Inventories	'
	Inventories
	Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. Certain components of the Company’s products are provided by a limited number of vendors, and the Company’s production and assembly operations are outsourced to third-party suppliers where substantially all of the Company’s inventory is located. Disruption of supply from key vendors or third-party suppliers may have a material adverse impact on the Company’s operations.
Equipment, Molds, Furniture, and Fixtures	'
	Equipment, Molds, Furniture, and Fixtures
	Equipment, molds, furniture, and fixtures are stated at cost and are depreciated using the straight-line method over their estimated useful lives ranging from three to ten years. Depreciation expense was $359,471, $145,775 and $86,636 for the years ended December 31, 2013, 2012 and 2011, respectively.
Goodwill	'
	Goodwill
	The Company has $1,095,355 of goodwill recorded as of December 31, 2013 that relates to the Minnesota reporting unit. The Company evaluates the carrying amount of goodwill on December 31 of each year and between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of the Minnesota reporting unit below its carrying amount. Such circumstances could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, (3) an adverse action or assessment by a regulator, or (4) a sustained significant drop in the Company’s stock price. When evaluating whether goodwill is impaired, the Company compares the fair value of the Minnesota reporting unit to the carrying amount, including goodwill. If the carrying amount of the Minnesota reporting unit exceeded its fair value, then the amount of the impairment loss would be measured. The impairment loss would be calculated by comparing the implied fair value of goodwill to its carrying amount. In calculating the implied fair value of goodwill, the fair value of the Minnesota reporting unit would be allocated to all of its other assets and liabilities based on their fair values. The excess of the fair value of the Minnesota reporting unit over the amount assigned to its other assets and liabilities is the implied fair value of goodwill. An impairment loss would be recognized when the carrying amount of goodwill exceeds its implied fair value.
	In evaluating whether the fair value of the Minnesota reporting unit was below its carrying amount, the Company used the market capitalization of the Company at December 31, 2013, which was approximately $575 million, to calculate an estimate of fair value of the Minnesota reporting unit. The Company determined that the percentage of the total market capitalization of the Company at December 31, 2013 attributable to the Minnesota reporting unit would have to be unreasonably low before the fair value of the Minnesota reporting unit would be less than its carrying amount. In making this determination, the Company evaluated the activity at the Minnesota reporting unit compared to the total Company activity, and considered the source and potential value of agreements currently in place, the source of recent product sales and development revenue growth, the source of total Company revenue and the source of cash generating activities. After performing the market capitalization analysis and concluding that the fair value of the Minnesota reporting unit was not below its carrying amount, the Company determined that no further detailed determination of fair value was required.
	The Company’s evaluation of goodwill resulted in no impairment losses in 2013, 2012 and 2011.
Patent Rights	'
	Patent Rights
	The Company capitalizes the cost of obtaining and defending patent rights when there are projected future cash flows for marketed or partnered products associated with the patent. These capitalized costs are being amortized on a straight-line basis over periods ranging from five to fifteen years beginning on the earlier of the date the patent is issued or the first commercial sale of product utilizing such patent rights. Amortization expense for the years ended December 31, 2013, 2012 and 2011 was $133,788, $85,253 and $81,535, respectively, and is recorded in general and administrative expenses in the consolidated statements of operations.
Impairment of Long-Lived Assets and Long-Lived Assets to Be Disposed Of	'
	Impairment of Long-Lived Assets and Long-Lived Assets to Be Disposed Of
	Long-lived assets, including patent rights, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset or asset group. This analysis can be very subjective as the Company relies upon signed distribution or license agreements with variable cash flows to substantiate the recoverability of long-lived assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.
	Each year the Company reviews patent costs for impairment and identifies patents related to products for which there are no signed distribution or license agreements or for which no revenues or cash flows are anticipated. In 2013, the Company recognized expense of $65,022 in connection with the write off of patent costs related to abandoned patents or patents no longer connected with current products. No impairment charges were recognized in 2012 or 2011. The gross carrying amount and accumulated amortization of patents, which are the only intangible assets of the Company subject to amortization, were $2,635,706 and $1,290,529, respectively, at December 31, 2013 and were $2,244,086 and $1,120,434, respectively, at December 31, 2012. The Company’s estimated aggregate patent amortization expense for the next five years is approximately $145,000, $152,000, $160,000, $160,000 and $160,000 in 2014, 2015, 2016, 2017 and 2018, respectively.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	Cash and cash equivalents are stated at cost, which approximates fair value.
	All short-term and long-term investments are U.S. Treasury bills or U.S. Treasury notes that are classified as held-to-maturity because the Company has the positive intent and ability to hold the securities to maturity. The securities are carried at their amortized cost. The fair value of all securities is determined by quoted market prices, which is a Level 1 fair value measurement. All long-term investments mature in less than two years. At December 31, 2013 the short-term investments had a fair value of $24,021,522 and a carrying value of $24,014,305 and the long-term investments had a fair value of $6,007,851 and a carrying value of $6,008,169. At December 31, 2012 the short-term investments had a fair value of $21,116,952 and a carrying value of $21,112,623 and the long-term investments had a fair value of $12,016,530 and a carrying value of $12,015,906.
Revenue Recognition	'
	Revenue Recognition
	The Company recognizes revenue from the sale of products and from license fees, milestones and royalties. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred and title has passed, (iii) the price is fixed or determinable and (iv) collectability is reasonably assured.
	The Company sells its proprietary reusable needle-free injectors and related disposable products to pharmaceutical partners and through medical product distributors. The Company’s reusable injectors and related disposable products are not interchangeable with any competitive products and must be used together. The Company recognizes revenue upon shipment when title transfers. The Company offers no price protection or return rights other than for customary warranty claims. Sales terms and pricing are governed by license and distribution agreements.
	Revenue arrangements with multiple deliverables are divided into separate units of accounting if certain criteria are met, including whether the deliverable has stand-alone value to the customer, the customer has a general right of return relative to the delivered item and delivery or performance of the undelivered item is probable and substantially within the vendor’s control. Arrangement consideration is allocated at the inception of the arrangement to all deliverables on the basis of their relative selling price. The selling price for each deliverable is determined using: (i) vendor-specific objective evidence of selling price (VSOE), if it exists, (ii) third-party evidence of selling price (TPE) if VSOE does not exist, and (iii) the Company’s best estimate of the selling price if neither VSOE nor TPE exists. For transactions entered into prior to January 1, 2011, revenue is recognized for each deliverable based upon the applicable revenue recognition criteria discussed above and upon acceptance of goods or performance of service. Effective January 1, 2011, for new or significantly modified transactions, the Company allocates revenue consideration, excluding contingent consideration, based on the relative selling prices of the separate units of accounting contained within an arrangement containing multiple deliverables.
	Royalty revenues are recognized in the quarter earned when the Company has information available to determine the royalty amount, however, the majority of the Company’s royalty revenues are recognized one quarter in arrears as information is typically not available to determine quarterly royalty earnings until royalty statements are received from partners.
	At December 31, 2013, $6,386,416 of non-refundable cash payments received have been recorded as deferred revenue in cases where the revenue is not immediately recognized due to the earnings process not yet having been completed.
Shipping and Handling Costs	'
	Shipping and Handling Costs
	The Company records shipping and handling costs in cost of product sales.
Stock-Based Compensation	'
	Stock-Based Compensation
	The Company records compensation expense associated with share based awards granted to employees at the fair value of the award on the date of grant. The expense is recognized over the period during which an employee is required to provide services in exchange for the award. The Company uses the Black-Scholes option valuation model to determine the fair value of stock options. The fair value model includes various assumptions, including the expected volatility and expected life of the awards.
Product Warranty	'
	Product Warranty
	The Company provides a warranty on its reusable needle-free injector devices. Warranty terms for these devices sold to end-users by dealers and distributors are included in the device instruction manual included with each device sold. Warranty terms for these devices sold to pharmaceutical partners who provide their own warranty terms to end-users are included in the contracts with the pharmaceutical partners. The Company is obligated to repair or replace, at the Company’s option, a needle-free injector device found to be defective due to use of defective materials or faulty workmanship. The warranty does not apply to any product that has been used in violation of instructions as to the use of the product or to any product that has been neglected, altered, abused or used for a purpose other than the one for which it was manufactured. The warranty also does not apply to any damage or defect caused by unauthorized repair or the use of unauthorized parts. The warranty period on a needle-free injector device is typically 24 months from either the date of retail sale of the device by a dealer or distributor or the date of shipment to a customer if specified by contract. The Company recognizes the estimated cost of warranty obligations at the time the products are shipped based on historical claims incurred by the Company. The Company increased the warranty liability in 2011 due to an increase in product sales. Actual warranty claim costs could differ from these estimates. Warranty liability activity is as follows:
		Balance at		Provisions		Claims			Balance at
		Beginning of							End of
		Year							Year
	2013	$	100,000	$	50,819	$	(50,819	)	$	100,000
	2012	$	100,000	$	72,893	$	(72,893	)	$	100,000
	2011	$	20,000	$	95,766	$	(15,766	)	$	100,000
Research and Development	'
	Research and Development
	Research and development costs are expensed as incurred.
Income Taxes	'
	Income Taxes
	Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. As of December 31, 2012, a valuation allowance was established to offset all of the Company’s deferred tax assets, and as of December 31, 2013, a valuation allowance was established to offset all of the U.S. deferred tax assets. For the year ended December 31, 2013, the Company recorded an income tax benefit of $300,000 after releasing $300,000 of the valuation allowance related to the Switzerland deferred tax assets.
Net Loss Per Share	'
	Net Loss Per Share
	Basic net loss per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed similar to basic net loss per share except that the weighted average shares outstanding are increased to include additional shares from the assumed exercise of stock options and warrants, if dilutive. The number of additional shares is calculated by assuming that outstanding stock options or warrants were exercised and that the proceeds from such exercise were used to acquire shares of common stock at the average market price during the reporting period. All potentially dilutive common shares were excluded from the calculation because they were anti-dilutive for all periods presented. Potentially dilutive securities at December 31, 2013, 2012 and 2011, excluded from dilutive loss per share as their effect is anti-dilutive, are as follows:
		2013		2012		2011
	Stock options and warrants		8,242,992		10,830,530		17,860,956

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Warranty Liability Activity	'
	Warranty liability activity is as follows:
		Balance at		Provisions		Claims			Balance at
		Beginning of							End of
		Year							Year
	2013	$	100,000	$	50,819	$	(50,819	)	$	100,000
	2012	$	100,000	$	72,893	$	(72,893	)	$	100,000
	2011	$	20,000	$	95,766	$	(15,766	)	$	100,000
Summary of Potentially Dilutive Securities Excluded from Dilutive Loss Per Share	'
	Potentially dilutive securities at December 31, 2013, 2012 and 2011, excluded from dilutive loss per share as their effect is anti-dilutive, are as follows:
		2013		2012		2011
	Stock options and warrants		8,242,992		10,830,530		17,860,956

Composition_of_Certain_Financi1

Composition of Certain Financial Statement Captions (Tables)	12 Months Ended
	Dec. 31, 2013
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Summary of Composition of Certain Financial Statement Captions	'
	December 31,			December 31,
	2013			2012
	Inventories:
	Raw material	$	1,056,054		$	609,016
	Work in process		3,034,321			—
	Finished goods		2,370,676			393,687
		$	6,461,051		$	1,002,703
	Equipment, molds, furniture and fixtures:
	Furniture, fixtures and office equipment	$	1,501,612		$	1,133,925
	Production molds and equipment		7,389,062			1,503,615
	Molds and tooling in process		424,521			2,948,249
	Less accumulated depreciation		(2,362,944	)		(2,002,685	)
		$	6,952,251		$	3,583,104
	Patent rights:
	Patent rights	$	2,635,706		$	2,244,086
	Less accumulated amortization		(1,290,529	)		(1,120,434	)
		$	1,345,177		$	1,123,652
	Accrued expenses and other liabilities:
	Accrued employee compensation and benefits	$	2,348,456		$	1,896,832
	Liabilities related to OTREXUP™ development and commercialization expenses		1,946,869			—
	Other liabilities		1,157,750			1,019,868
		$	5,453,075		$	2,916,700

Leases_Tables

Leases (Tables)	12 Months Ended
	Dec. 31, 2013
Leases [Abstract]	'
Summary of Future Minimum Lease Payments	'
	Future minimum lease payments under operating leases with remaining terms in excess of one year as of December 31, 2013 were as follows:
		Amount
	2014	$	372,767
	2015		569,967
	2016		581,377
	2017		592,905
	2018		604,554
	Thereafter		1,037,921
	Total future minimum lease payments	$	3,759,491

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Income before Income Tax Domestic and Foreign	'
	Income (loss) before income taxes was derived from the following jurisdictions:
		2013			2012			2011
	U.S.	$	(21,568,727	)	$	(16,477,710	)	$	(3,977,263	)
	Switzerland		761,951			5,050,260			(410,657	)
		$	(20,806,776	)	$	(11,427,450	)	$	(4,387,920	)
Summary of Effective Tax Rates Differ from Statutory Income Tax Rates	'
	Effective tax rates differ from statutory income tax rates in the years ended December 31, 2013, 2012 and 2011 as follows:
		2013			2012			2011
	Statutory income tax rate		(34.0	)%		(34.0	)%		(34.0	)%
	State income taxes		(1.0	)		(3.6	)		(1.6	)
	Valuation allowance increase (decrease)		28.8			29.8			(4.3	)
	Effect of foreign operations		(0.7	)		(8.5	)		1.9
	Change in unused net operating loss and credit carryforwards		(1.0	)		14			35.5
	Nondeductible items		6.5			0.6			1.8
	Other		—			1.7			0.7
			(1.4	)%		0	%		0	%
Summary of Deferred Tax Assets	'
	Deferred tax assets (liabilities) as of December 31, 2013 and 2012 consist of the following:
		2013			2012
	Net operating loss carryforward – U.S.	$	28,832,000		$	22,411,000
	Net operating loss carryforward – Switzerland		4,556,000			5,551,000
	Research and development tax credit carryforward		2,589,000			1,292,000
	Deferred revenue		320,000			398,000
	Depreciation and amortization		(105,000	)		115,000
	Stock-based compensation		1,581,000			1,573,000
	Other		93,000			1,150,000
			37,866,000			32,490,000
	Less valuation allowance		(37,566,000	)		(32,490,000	)
		$	300,000		$	—

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Summary of Stock Option Activity	'
	A summary of stock option activity under the Plan as of December 31, 2013 and the changes during the three years then ended is as follows:
		Number of			Weighted			Weighted			Aggregate
		Shares			Average			Average			Intrinsic
					Exercise			Remaining			Value
					Price			Contractual			($)
					($)			Term (Years)
	Outstanding at December 31, 2010		7,657,876			1.18
	Granted/Issued		972,409			1.75
	Exercised		(750,063	)		1.37						488,724
	Cancelled/Forfeited		(94,550	)		3.21
	Outstanding at December 31, 2011		7,785,672			1.21
	Granted/Issued		1,334,731			3.18
	Exercised		(1,164,636	)		1.2						2,620,360
	Cancelled/Forfeited		(141,206	)		4.06
	Outstanding at December 31, 2012		7,814,561			1.49
	Granted/Issued		1,129,380			3.99
	Exercised		(981,385	)		0.72						3,319,471
	Cancelled/Forfeited		(264,664	)		3.48
	Outstanding at December 31, 2013		7,697,892			1.89			6.3			19,883,523
	Exercisable at December 31, 2013		6,207,584			1.47			5.6			18,605,127
Assumptions Used in Fair Value Measurement of Options Granted	'
	The weighted average expected life is based on both historical and anticipated employee behavior.
		December 31,
		2013			2012			2011
	Risk-free interest rate		0.9	%		0.7	%		1.7	%
	Annualized volatility		62	%		61	%		59	%
	Weighted average expected life, in years		6			5			5
	Expected dividend yield		0	%		0	%		0	%
Summary of Warrant Activity	'
	Warrant activity is summarized as follows:
		Number of			Weighted
		Shares			Average Price ($)
	Outstanding at December 31, 2010		17,685,059			1.56
	Exercised		(4,107,759	)		1.37
	Cancelled		(3,502,016	)		1.5
	Outstanding at December 31, 2011		10,075,284			1.66
	Exercised		(7,056,075	)		1.53
	Cancelled		(3,240	)		2
	Outstanding at December 31, 2012		3,015,969			1.98
	Exercised		(1,470,869	)		1.11
	Cancelled		(1,000,000	)		3.78
	Outstanding at December 31, 2013		545,100			1
Schedule of Performance Stock Unit Awards and Restricted Stock Granted Under Long Term Incentive Program	'
	The performance stock unit awards and restricted stock granted under the long term incentive program are summarized in the following table:
		Performance Stock Units						Restricted Stock
		Number of			Weighted			Number of			Weighted
		Shares			Average Fair			Shares			Average Fair
					Value ($)						Value ($)
	Outstanding at December 31, 2010		—			—			—			—
	Granted		182,000			1.66			—			—
	Vested		—			—			—			—
	Forfeited/Expired		—			—			—			—
	Outstanding at December 31, 2011		182,000			1.66			—			—
	Granted		137,715			4.26			—			—
	Vested		—			—			—			—
	Forfeited/Expired		—			—			—			—
	Outstanding at December 31, 2012		319,715			2.78			—			—
	Granted		185,185			3.96			185,185			3.96
	Vested		—			—			—			—
	Forfeited/Expired		(98,237	)		3.32			(29,461	)		3.96
	Outstanding at December 31, 2013		406,663			3.19			155,724			3.96

Segment_Information_and_Signif1

Segment Information and Significant Customers (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Revenues By Customer Location	'
	Revenues by customer location are summarized as follows:
		For the Years Ended December 31,
		2013		2012		2011
	United States of America	$	16,479,855	$	16,964,635	$	10,236,304
	Europe		3,901,422		4,936,981		5,765,909
	Other		237,223		673,962		456,279
		$	20,618,500	$	22,575,578	$	16,458,492
Revenues By Product Type	'
	Revenues by product type:
		For the Years Ended December 31,
		2013		2012		2011
	Injection devices and supplies	$	18,156,217	$	12,642,537	$	14,360,078
	Transdermal gel products		2,462,283		9,933,041		2,098,414
		$	20,618,500	$	22,575,578	$	16,458,492
Summary of Significant Customers Comprising 10% or More of Total Revenue	'
	The following summarizes significant customers comprising 10% or more of total revenue for the years ended December 31:
		2013		2012		2011
	Teva	$	13,559,541	$	7,495,978	$	8,175,990
	Ferring		3,827,098		4,933,369		5,764,208
	Actavis		1,489,942		6,770,635		1,024,240
Summary of Significant Customers Comprising 10% or More of Outstanding Accounts Receivable	'
	The following summarizes significant customers comprising 10% or more of outstanding accounts receivable as of December 31:
		2013		2012
	Teva	$	436,632	$	1,033,203
	Ferring		562,576		622,885
	Actavis		—		522,807

Quarterly_Financial_Data_unaud1

Quarterly Financial Data (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Data	'
			First			Second			Third			Fourth
	2013:00:00
	Total revenues (1)		$	4,528,222		$	5,837,544		$	5,507,824		$	4,744,910
	Gross profit (1)			2,501,079			2,356,862			2,503,222			4,060,107
	Net loss			(3,408,448	)		(5,103,256	)		(6,359,957	)		(5,635,115	)
	Net loss per common share (2)			(0.03	)		(0.04	)		(0.05	)		(0.04	)
	Weighted average shares			126,106,713			126,462,677			127,162,064			127,835,641
	2012:00:00
	Total revenues		$	6,864,542		$	4,523,942		$	5,685,917		$	5,501,177
	Gross profit			4,873,711			1,992,831			2,389,428			3,799,136
	Net loss			(74,394	)		(2,807,072	)		(3,534,239	)		(5,011,745	)
	Net loss per common share (2)			(0.00	)		(0.03	)		(0.03	)		(0.04	)
	Weighted average shares			103,658,571			104,551,742			108,961,792			123,436,025
	-1	Total revenues in the fourth quarter of 2013 included over $1.1 million more licensing and royalty revenue than in each of the prior three quarters, resulting in a higher gross profit as there were no associated costs with these revenues. Also impacting gross profit in the fourth quarter was development revenue having a higher gross profit than development revenue in prior quarters.
	-2	Net loss per common share is computed based upon the weighted average number of shares outstanding during each period. Basic and diluted loss per share amounts are identical as the effect of potential common shares is anti-dilutive.

Description_of_Business_Additi

Description of Business - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013
	Customer
	Facility
	Patient
	site
Description Of Business [Abstract]	'
Number of patients enrolled in the study	39
Number of investigative sites	9
Number of primary customers	2
Number of facility locations	2

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Subsidiaries
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Wholly-owned subsidiaries of Antares Pharma	3	'	'
Accounts receivable balance due	95.00%	'	'
Bad debt expense	$0	$0	$0
Allowance for doubtful accounts balance	10,000	10,000	'
Depreciation expense	359,471	145,775	86,636
Goodwill	1,095,355	1,095,355	'
Market capitalization of the Company	575,000,000	'	'
Goodwill impairment loss	0	0	0
Amortization expense	133,788	85,253	81,535
Anticipated revenues from patents due to agreement	0	'	'
Anticipated cash flow from patents due to agreement	0	'	'
Impairment charges	0	'	'
Patent rights	2,635,706	2,244,086	'
Accumulated amortization of patents	1,290,529	1,120,434	'
Aggregate patent amortization expense, 2014	145,000	'	'
Aggregate patent amortization expense, 2015	152,000	'	'
Aggregate patent amortization expense, 2016	160,000	'	'
Aggregate patent amortization expense, 2017	160,000	'	'
Aggregate patent amortization expense, 2018	160,000	'	'
Patent write off	65,022	'	'
Short-term investments fair value	24,021,522	21,116,952	'
Short term investments	24,014,305	21,112,623	'
Long-term investments fair value	6,007,851	12,016,530	'
Long term investments	6,008,169	12,015,906	'
Long-term investments maturity	'2 years	'	'
Non-refundable cash payments	6,386,416	'	'
Method used for fair value assumption	'Black-Scholes option valuation model	'	'
Warranty period of device	'24 months	'	'
Valuation allowance for deferred tax assets	37,566,000	32,490,000	'
Income tax provision (benefit)	-300,000	'	'
Switzerland [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Valuation allowance for deferred tax assets	300,000	'	'
Us Deferred Tax Assets [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Income tax provision (benefit)	($300,000)	'	'
Maximum [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Debt instruments maturity	'90 days	'	'
Estimated useful lives	'10 years	'	'
Capitalized cost being amortized over periods	'15 years	'	'
Minimum [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Estimated useful lives	'3 years	'	'
Capitalized cost being amortized over periods	'5 years	'	'

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Summary of Warranty Liability Activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Movement In Standard And Extended Product Warranty Increase Decrease [Roll Forward]	'	'	'
Balance at Beginning of Year	$100,000	$100,000	$20,000
Provisions	50,819	72,893	95,766
Claims	-50,819	-72,893	-15,766
Balance at End of Year	$100,000	$100,000	$100,000

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Dilutive Loss Per Share (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Equity [Abstract]	'	'	'
Stock options and warrants	8,242,992	10,830,530	17,860,956

Composition_of_Certain_Financi2

Composition of Certain Financial Statement Captions - Summary of Composition of Certain Financial Statement Captions (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Inventories:	'	'
Raw material	$1,056,054	$609,016
Work in process	3,034,321	'
Finished goods	2,370,676	393,687
Inventory, Total	6,461,051	1,002,703
Equipment, molds, furniture and fixtures:	'	'
Furniture, fixtures and office equipment	1,501,612	1,133,925
Production molds and equipment	7,389,062	1,503,615
Molds and tooling in process	424,521	2,948,249
Less accumulated depreciation	-2,362,944	-2,002,685
Equipment, molds, furniture and fixtures, Total	6,952,251	3,583,104
Patent rights:	'	'
Patent rights	2,635,706	2,244,086
Less accumulated amortization	-1,290,529	-1,120,434
Patent rights, Total	1,345,177	1,123,652
Accrued expenses and other liabilities:	'	'
Accrued employee compensation and benefits	2,348,456	1,896,832
Other liabilities	1,157,750	1,019,868
Accrued expenses and other liabilities	5,453,075	2,916,700
Otrexuptm [Member]	'	'
Accrued expenses and other liabilities:	'	'
Liabilities related to OTREXUPb" development and commercialization expenses	$1,946,869	'

Leases_Additional_Information_

Leases - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	sqft
Leases [Abstract]	'	'	'
Rent expense, net	$453,142	$325,971	$261,171
Lease agreement for office, research and development	18,000	'	'

Leases_Summary_of_Future_Minim

Leases - Summary of Future Minimum Lease Payments (Detail) (USD $)	Dec. 31, 2013
Operating Leases Future Minimum Payments Due [Abstract]	'
2014	$372,767
2015	569,967
2016	581,377
2017	592,905
2018	604,554
Thereafter	1,037,921
Total future minimum lease payments	$3,759,491

Income_Taxes_Additional_Inform

Income Taxes - Additional Informations (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Operating Loss Carryforwards [Line Items]	'	'
Period of incurred losses for both book and tax purposes	'3 years	'
Net operating loss carryforwards were used to fully offset book and tax income	$500,000	$5,500,000
Valuation allowance for deferred tax assets	37,566,000	32,490,000
Increased and decreased total valuation allowance	5,076,000	3,579,000
Benefit of deferred tax assets	500,000	5,500,000
Unrecognized tax benefits	0	0
Interest or penalties charged in relation to unrecognized tax benefits	0	'
Interest or penalties accrued in relation to unrecognized tax benefits	0	'
Total unrecognized tax benefits changing period	'12 months	'
Switzerland [Member]	'	'
Operating Loss Carryforwards [Line Items]	'	'
Valuation allowance for deferred tax assets	300,000	'
U.S Federal Tax [Member]	'	'
Operating Loss Carryforwards [Line Items]	'	'
Net operating loss carry forward	87,100,000	'
Expiring net operating loss carryforward amount	5,200,000	'
Research credit carryforward	2,600,000	'
Foreign Tax Authority [Member]	'	'
Operating Loss Carryforwards [Line Items]	'	'
Net operating loss carry forward	33,700,000	'
Expiring net operating loss carryforward amount	$33,300,000	'
Expiring period of net operating loss carryforward	'3 years	'

Income_Taxes_Schedule_of_Incom

Income Taxes - Schedule of Income before Income Tax Domestic and Foreign (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments [Abstract]	'	'	'
Income (loss) before income taxes, US	($21,568,727)	($16,477,710)	($3,977,263)
Income (loss) before income taxes, Switzerland	761,951	5,050,260	-410,657
Net loss	($20,806,776)	($11,427,450)	($4,387,920)

Income_Taxes_Summary_of_Effect

Income Taxes - Summary of Effective Tax Rates Differ from Statutory Income Tax Rates (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]	'	'	'
Statutory income tax rate	-34.00%	-34.00%	-34.00%
State income taxes	-1.00%	-3.60%	-1.60%
Valuation allowance increase (decrease)	28.80%	29.80%	-4.30%
Effect of foreign operations	-0.70%	-8.50%	1.90%
Change in unused net operating loss and credit carryforwards	-1.00%	14.00%	35.50%
Nondeductible items	6.50%	0.60%	1.80%
Other	'	1.70%	0.70%
Effective income tax rate, Total	-1.40%	0.00%	0.00%

Income_Taxes_Summary_of_Deferr

Income Taxes - Summary of Deferred Tax Assets (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Net operating loss carryforward - U.S.	$28,832,000	$22,411,000
Net operating loss carryforward - Switzerland	4,556,000	5,551,000
Research and development tax credit carryforward	2,589,000	1,292,000
Deferred revenue	320,000	398,000
Depreciation and amortization	-105,000	115,000
Stock-based compensation	1,581,000	1,573,000
Other	93,000	1,150,000
Deferred tax asset, Total	37,866,000	32,490,000
Less valuation allowance	-37,566,000	-32,490,000
Deferred tax assets, net	$300,000	'

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2010

Dec. 31, 2013

Nov. 30, 2012

Oct. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Long Term Incentive Program [Member]

Directors [Member]

Directors [Member]

Directors [Member]

Minimum [Member]

Maximum [Member]

Discretionary Shares [Member]

Discretionary Shares [Member]

Discretionary Shares [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Performance Stock Units [Member]

Performance Stock Units [Member]

Performance Stock Units [Member]

Performance Stock Units [Member]

Restricted Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Long Term Incentive Program [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,759,868

12,500,000

'

14,259,868

14,375,000

'

'

'

Common stock price per shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4

$4

'

'

'

'

'

'

Proceeds from issuance of common stock, net

$0

$53,328,188

$21,280,718

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$53,328,188

'

'

'

'

'

'

Common stock offering expenses

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,711,284

'

'

'

'

'

'

Share-based compensation arrangement by share-based payment award, number of shares authorized

15,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum number of shares of stock granted to one participant

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum percentage of exercise price

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contractual term of options granted

'

'

'

'10 years

'

'

'

'10 years

'11 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares available for grant under the plan

247,400

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost related to nonvested outstanding stock awards

350,000

'

'

'

'

'

'

'

'

'

'

'

2,549,656

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average period expected to be recognized

'5 months

'

'

'

'

'

'

'

'

'

'

'

'2 years 2 months 12 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Recognized compensation cost related to stock options

'

'

'

'

679,500

560,000

46,500

'

'

8,722

301,017

771,491

1,364,000

1,164,000

1,055,000

'

'

'

'

125,000

'

'

'

'

'

'

'

'

Per share weighted average fair value of options granted

'

'

'

'

'

'

'

'

'

'

'

'

$2.26

$1.64

$0.89

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from the issuance of stock options

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

692,348

792,203

1,025,985

'

'

'

Issuance of shares of common stock Options

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

981,385

965,597

750,063

'

'

'

Exercised stock option which did not generate cash

'

'

'

'

'

'

'

'

'

'

'

'

'

583,344

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of shares of common stock from cashless option exercises

'

'

'

'

'

'

'

'

'

'

'

'

384,305

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from warrant exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,634,490

10,787,210

4,994,451

Issuance of shares of common stock Warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,470,869

7,056,075

3,725,272

Share based payment performance awards shares granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

35,000

145,454

'

'

'

'

'

'

'

'

'

'

'

Share based payment discretionary awards shares granted

'

'

'

'

'

'

'

'

'

0

60,000

368,267

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares withheld to meet employees' minimum statutory income tax obligation

30,153

11,165

121,182

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments for the employees' minimum statutory income tax obligation

104,329

28,916

233,291

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock grants unvested

'

'

'

'

212,618

'

'

'

'

'

'

'

'

'

'

319,715

182,000

406,663

'

'

'

'

'

'

'

'

'

'

Weighted average fair value of shares granted

$4.01

$2.84

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options granted under long term incentive program vesting period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

Performance stock unit awards expenses

'

'

'

$259,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Equity_Summary_of

Stockholders' Equity - Summary of Stock Option Activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stockholders Equity Note [Abstract]	'	'	'
Number of Shares Outstanding, Beginning	7,814,561	7,785,672	7,657,876
Weighted Average Exercise Price Outstanding, Beginning Balance	$1.49	$1.21	$1.18
Number of Shares Granted/Issued	1,129,380	1,334,731	972,409
Number of Shares Exercised	-981,385	-1,164,636	-750,063
Number of Shares Cancelled/Forfeited	-264,664	-141,206	-94,550
Number of Shares Outstanding, Ending	7,697,892	7,814,561	7,785,672
Number of Shares Exercisable, Ending	6,207,584	'	'
Weighted Average Exercise Price Granted/Issued	$3.99	$3.18	$1.75
Weighted Average Exercise Price Exercised	$0.72	$1.20	$1.37
Weighted Average Exercise Price Cancelled/Forfeited	$3.48	$4.06	$3.21
Weighted Average Exercise Price Outstanding, Ending Balance	$1.89	$1.49	$1.21
Weighted Average Exercise Price Exercisable, Ending Balance	$1.47	'	'
Weighted Average Remaining Contractual Term Outstanding, Ending	'6 years 3 months 18 days	'	'
Weighted Average Remaining Contractual Term Exercisable, Ending	'5 years 7 months 6 days	'	'
Aggregate Intrinsic Value, Exercised	$3,319,471	$2,620,360	$488,724
Aggregate Intrinsic Value Outstanding, Ending	19,883,523	'	'
Aggregate Intrinsic Value Exercisable, Ending	$18,605,127	'	'

Stockholders_Equity_Assumption

Stockholders' Equity - Assumptions Used in Fair Value Measurement of Options Granted (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stockholders Equity Note [Abstract]	'	'	'
Risk-free interest rate	0.90%	0.70%	1.70%
Annualized volatility	62.00%	61.00%	59.00%
Weighted average expected life, in years	'6 years	'5 years	'5 years
Expected dividend yield	0.00%	0.00%	0.00%

Stockholders_Equity_Summary_of1

Stockholders' Equity - Summary of Warrant Activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stockholders Equity Note [Abstract]	'	'	'
Warrants Number of Shares, Beginning balance	3,015,969	10,075,284	17,685,059
Warrants Number of Shares, Exercised	-1,470,869	-7,056,075	-4,107,759
Warrants Number of Shares, Cancelled	-1,000,000	-3,240	-3,502,016
Warrants Number of Shares, Ending balance	545,100	3,015,969	10,075,284
Warrants Weighted Average Price, Beginning balance	1.98	1.66	1.56
Warrants Weighted Average Price, Exercised	$1.11	$1.53	$1.37
Warrants Weighted Average Price, Cancelled	$3.78	$2	$1.50
Warrants Weighted Average Price, Ending balance	1	1.98	1.66

Stockholders_Equity_Schedule_o

Stockholders' Equity - Schedule of Performance Stock Unit Awards and Stock Option Granted Under Long Term Incentive Program (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Performance Stock Units [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Number of Shares, Beginning Balance	319,715	182,000	'
Number of Shares, Granted	185,185	137,715	182,000
Number of Shares, Forfeited/Expired	-98,237	'	'
Number of Shares, Ending Balance	406,663	319,715	182,000
Weighted Average Fair Value, Beginning Balance	$2.78	$1.66	'
Weighted Average Fair Value, Granted	$3.96	$4.26	$1.66
Weighted Average Fair Value, Forfeited/Expired	$3.32	'	'
Weighted Average Fair Value, Ending Balance	$3.19	$2.78	$1.66
Restricted Stock [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Number of Shares, Beginning Balance	'	'	'
Number of Shares, Granted	185,185	'	'
Number of Shares, Forfeited/Expired	-29,461	'	'
Number of Shares, Ending Balance	155,724	'	'
Weighted Average Fair Value, Granted	$3.96	'	'
Weighted Average Fair Value, Forfeited/Expired	$3.96	'	'
Weighted Average Fair Value, Ending Balance	$3.96	'	'

Employee_401k_Savings_Plan_Add

Employee 401(k) Savings Plan - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Schedule Of Sale Of Subsidiary [Abstract]	'	'	'
Maximum employee plan contribution percentage of compensation	50.00%	'	'
Company plan contributions	$230,000	$173,000	$109,000

License_Agreements_Additional_

License Agreements - Additional Information (Detail) (USD $)

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

Nov. 23, 2013

Jan. 31, 2011

Dec. 31, 2007

Sep. 30, 2006

Jul. 31, 2006

Dec. 31, 2013

Nov. 23, 2013

Nov. 23, 2013

Dec. 31, 2007

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Jun. 30, 2000

Jan. 31, 2013

Product

Product

Performance obligations [Member]

Realizing a defined level of net sales [Member]

Teva License Supply And Distribution Agreement [Member]

Teva License Supply And Distribution Agreement [Member]

Teva License Supply And Distribution Agreement [Member]

Teva License Supply And Distribution Agreement [Member]

Ferring Agreements [Member]

Pfizer License Agreement [Member]

ANI License Agreement [Member]

Daewoong Development And License Agreement [Member]

Parent Company [Member]

Teva [Member]

Deferred Revenue Arrangement [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non refundable upfront payment

$5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Milestone payment receivable

'

'

'

'

'

'

5,000,000

10,000,000

'

'

'

'

'

'

'

'

Revenue recognized

'

'

'

'

'

571,000

'

'

'

'

'

'

'

'

'

'

Recognition of deferred revenue

'

'

'

'

'

$4,429,000

'

'

'

'

'

'

'

'

'

'

Revenue recognition period of deliverables

'

'

'

'

'

'35 months

'

'

'

'

'

'

'

'

'

'

Percentage of profit distribution

'

'

'

'

'

'

'

'

'

'

50.00%

50.00%

'

'

'

'

Term of the agreement

'

'

'

'

'

'

'

'

'

'7 years

'

'

'

'

'10 years

'15 years

Period for automatic renewals

'

'

'2 years

'1 year

'

'1 year

'

'

'

'

'

'

'

'

'

'

Number of undisclosed patient-administered pharmaceutical products

'

2

2

'

'

'

'

'

'

'

'

'

'

'

'

'

Device or product filed period

'

'

'

'

'12 months

'

'

'

'12 months

'

'

'

'

'

'

'

Period of terminated by either party

'

'

'

'6 months

'

'

'

'

'

'

'

'

'

'

'

'

Consultancy Services Agreement period, with Ferring

'

'

'

'

'

'

'

'

'

'

'

'

'12 months

'

'

'

Recognition period for exclusive license agreement payments

'

'

'

'

'

'

'

'

'

'

'

'

'12 months

'

'

'

Period for receiving royalties

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

Revenue_Recognition_Additional

Revenue Recognition - Additional Information (Detail) (USD $)	0 Months Ended		12 Months Ended
	Jan. 31, 2011	Dec. 31, 2007	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2011
	Product	Product	Licensing Agreements [Member]	Licensing Agreements [Member]	Development and Supply Agreement [Member]
Deferred Revenue Arrangement [Line Items]	'	'	'	'	'
Number of undisclosed patient-administered pharmaceutical products	2	2	'	'	'
Recognition of revenue previously deferred	'	'	$62,225	$337,776	$304,600
Recognition of cost previously deferred	'	'	'	$408,250	'

Segment_Information_and_Signif2

Segment Information and Significant Customers - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013
	Segment
Segment Reporting Information [Line Items]	'
Number of operating segment	1
Outstanding accounts receivable	10.00%
Sales [Member]	'
Segment Reporting Information [Line Items]	'
Total Revenue	10.00%

Segment_Information_and_Signif3

Segment Information and Significant Customers - Revenues By Customer Location (Detail) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	$4,744,910	$5,507,824	$5,837,544	$4,528,222	$5,501,177	$5,685,917	$4,523,942	$6,864,542	$20,618,500	$22,575,578	$16,458,492
United States of America [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	'	'	'	'	'	'	'	'	16,479,855	16,964,635	10,236,304
Europe [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	'	'	'	'	'	'	'	'	3,901,422	4,936,981	5,765,909
Other [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	'	'	'	'	'	'	'	'	$237,223	$673,962	$456,279

Segment_Information_and_Signif4

Segment Information and Significant Customers - Revenues By Product Type (Detail) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	$4,744,910	$5,507,824	$5,837,544	$4,528,222	$5,501,177	$5,685,917	$4,523,942	$6,864,542	$20,618,500	$22,575,578	$16,458,492
Injection devices and supplies [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	'	'	'	'	'	'	'	'	18,156,217	12,642,537	14,360,078
Transdermal gel products [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	'	'	'	'	'	'	'	'	$2,462,283	$9,933,041	$2,098,414

Segment_Information_and_Signif5

Segment Information and Significant Customers - Summary of Significant Customers Comprising 10% or More of Total Revenue (Detail) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	$4,744,910	$5,507,824	$5,837,544	$4,528,222	$5,501,177	$5,685,917	$4,523,942	$6,864,542	$20,618,500	$22,575,578	$16,458,492
Teva [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	'	'	'	'	'	'	'	'	13,559,541	7,495,978	8,175,990
Ferring [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	'	'	'	'	'	'	'	'	3,827,098	4,933,369	5,764,208
Actavis [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	'	'	'	'	'	'	'	'	$1,489,942	$6,770,635	$1,024,240

Segment_Information_and_Signif6

Segment Information and Significant Customers - Summary of Significant Customers Comprising 10% or More of Outstanding Accounts Receivable (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Teva [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Outstanding accounts receivable	$436,632	$1,033,203
Ferring [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Outstanding accounts receivable	562,576	622,885
Actavis [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Outstanding accounts receivable	'	$522,807

Quarterly_Financial_Data_unaud2

Quarterly Financial Data (unaudited) - Quarterly Financial Data (Detail) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Selected Quarterly Financial Information [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	$4,744,910	$5,507,824	$5,837,544	$4,528,222	$5,501,177	$5,685,917	$4,523,942	$6,864,542	$20,618,500	$22,575,578	$16,458,492
Gross profit	4,060,107	2,503,222	2,356,862	2,501,079	3,799,136	2,389,428	1,992,831	4,873,711	11,421,270	13,055,106	9,661,300
Net loss	($5,635,115)	($6,359,957)	($5,103,256)	($3,408,448)	($5,011,745)	($3,534,239)	($2,807,072)	($74,394)	($20,506,776)	($11,427,450)	($4,387,920)
Net loss per common share	($0.04)	($0.05)	($0.04)	($0.03)	($0.04)	($0.03)	($0.03)	$0	'	'	'
Weighted average shares	127,835,641	127,162,064	126,462,677	126,106,713	123,436,025	108,961,792	104,551,742	103,658,571	'	'	'

Quarterly_Financial_Data_unaud3

Quarterly Financial Data (unaudited) - Quarterly Financial Data (Parenthetical) (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013
Selected Quarterly Financial Information [Abstract]	'
Licensing and royalty revenue in excess of licensing and royalty revenue in each of the prior three quarters	$1.10